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INTRODUCTION 
 
Even in the modern era of advanced medical, surgical and critical care interventions, 
acute myocardial infarction (AMI) remains a disease that is associated with considerable 
morbidity and mortality.  In recent years, its prevalence seems to have been on the increase 
whereas the mean age of coronary artery disease (CAD) has decreased. Although coronary 
artery disease (CAD) primarily occurs in patients over the age of 40, many younger men and 
women can still be affected. Most studies have used an age cut-off of 40 to 45 years to define 
"young" patients with CAD and AMI.1-5. The prevalence of CAD in younger subjects is 
difficult to establish accurately since it is frequently a silent process and subclinical. An 
autopsy study of 760 young (age 15 to 34 years) victims of accidents, suicides, or homicides6 
showed advanced coronary atheromata in 2 percent of men and no women. An advanced 
lesion was present in 20 and 8 percent of men and women aged 30 to 34, respectively, while 
19 and 8 percent, respectively, had a ≥ 40 percent stenosis of the left anterior descending 
artery. 
There are also limited data on the frequency of AMI in younger subjects. In the 
Framingham Heart Study, the incidence of AMI over a 10-year follow-up was 12.9/1000 in 
men 30 to 34 years old and 5.2/1000 in women 35 to 44 years old7. The incidence of AMI 
was eight to nine times greater in men and women aged 55 to 64 years. In few other studies, 4 
to 10 percent of patients with AMI were ≤ 40 or 45 years of age 8-10.  In two series of patients 
with CAD at ≤ 40 years of age, women comprised only 5.6 and 11.4 % of patients 8-11. 
Although CAD is an uncommon entity in young patients, it constitutes an important problem 
for the patient and the treating physician because of the devastating effect of this disease on 
the more active lifestyle of young patients. The disease carries a significant morbidity, 
psychological effects, and financial constraints for the person and the family. 
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A number of studies have shown significant differences in the risk factor profile and 
coronary angiographic patterns between young and older patients with acute ST elevation 
myocardial infarction (STEMI) 12-16. Traditional risk factors of CAD are prevalent in young 
patients with acute STEMI but with a different pattern compared to their older counterparts 14, 
17, 18. These differences may cause different treatment strategies and outcome among these 
patients. 
The epidemiology, clinical spectrum of myocardial infarction is significantly different 
in developing countries compared to the western world. These differences can be attributable 
to multiple factors including increasing average life span, tobacco use, decreased physical 
activity, unhealthy diet and psychosocial factors. CAD occurs in Asian Indians 5–10 years 
earlier than in other populations around the world. The mean age for first presentation of 
acute myocardial infarction in Indians is 53 years 19-22. Prevention of these deaths in young 
people should become a national health priority.  A strategy involving prevention of CAD 
long before its onset will be more cost-effective than providing interventions at a stage when 
the disease is well established. In India, mortality attributable to CVD is expected to rise by 
103% in men and by 90% in women from 1985 to 2015 23.  
While the literature from developed countries is abundant in data highlighting various 
aspects of myocardial infarction in young patients, only a few studies have been published in 
India. How far the changes in the epidemiology of MI have occurred in India is not clearly 
known.  There is a need to collect the data from our own community, compare it with the 
world literature and analyze if the changing epidemiology of MI in young patients is also 
seen in our country. This study was undertaken with these specific objectives to analyze the 
clinical and angiographic variables in young Indian patients.  
 
 
  
 
 
  REVIEW OF 
LITERATURE  
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REVIEW OF LITERATURE 
History of Coronary Artery Disease 
                Symptoms related to angina pectoris and myocardial infarction were even found 
in ancient Egyptian papyruses dated approximately 3500 years back. It was in the late 16th 
and 17thcenturies that a breakthrough was made in the process of understanding this lethal 
disease. The first study of heart in the world, perceiving relation between loss of 
consciousness and arrhythmia with an account of ischemia and myocardial infarction was put 
forth as a text in `Practica Medicinalis’ by Bishop Thomas of Wroclaw (1297-1378)24. 
In the 18th century, better knowledge of coronary vascular anatomy lead to the real 
discovery of the ischemic heart disease and myocardial infarction by a physician who 
announced his observation in 1768. He was an English physician, William Heberden (1710-
1801). It was Heberden who was associated with the discovery and for a long time even in 
the 19th century, the disease was called as “Heberden’s disease”24, 25. 
After Heberden’s clinical description of angina, it took almost a century for 
pathologists to focus their attention on coronary arteries and describe thrombotic occlusions 
in addition to “ossification”. In 1879, the pathologist Ludwig Hekben concluded that 
myocardial infarction is caused by coronary thrombosis secondary to sclerotic changes in the 
coronaries26. In 1910 two Russian clinicians described five patients with the clinical picture 
of acute MI27.Two years later, Sir James. B. Herrick emphasized total bed rest as the 
treatment for this condition28 and by 1919 had used electrocardiography to diagnose it29. 
Two seminal developments in the 1960s radically changed our understanding and 
management of acute myocardial infarction. The National Heart, Lung, and Blood Institute 
(NHLBI) established the Framingham Heart Study in 1948 with the goal of understanding 
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how heart disease developed by studying the lifestyles of the residents of Framingham, 
Massachusetts USA30.  The first description of their findings, “Factors of Risk in the 
Development of Coronary Heart Disease,” indicated that elevations in blood pressure and 
cholesterol levels were associated with an increased incidence of ischemic heart disease and 
acute myocardial infarction. The study also showed a high frequency of MI among women, 
which often occurred later in life than it did in men. The institution by the NHLBI of national 
programs to educate clinicians and the public about the importance of controlling these risk 
factors have contributed to dramatic improvements in age-adjusted cardiac death rates31. 
With the identification of these coronary risk factors and others that followed, the veil 
that masked the underlying mechanisms in angina and myocardial infarction was lifted, and 
the concept that coronary heart disease and its complications could be prevented was 
introduced. Increasingly large multicenter clinical trials subsequently showed that both 
primary and secondary prevention was possible when steps were taken to lower blood 
pressure and serum total cholesterol. Fortunately, drugs to reduce these risk factors safely 
became available as a result of a series of productive collaborations between industry and 
academic medicine. 
Coronary Care Units 
Until 1961, patients with acute MI, if fortunate enough to survive until they reached a 
hospital, were placed in beds located throughout the hospital and far enough away from 
nurses’ stations that their rest would not be disturbed. Patients were commonly found dead in 
their beds, presumably from arrhythmia. Indeed, the risk of death occurring in the hospital 
was approximately 30%. The development of the coronary care unit32, which provided 
continuous monitoring of the electrocardiogram, closed-chest cardiac resuscitation, and 
5 
 
external defibrillation reduced in-hospital mortality by half among patients admitted with 
acute myocardial infarction. 
Physiology, Cardiac Catheterization, Angioplasty and surgery 
 
The publication of De Motu Cordis in 1628, William Harvey’s description of the 
circulation and the function of the heart33, set the stage for the physiological era several 
centuries later. The19th-century French physiologist Claude Bernard catheterized animals 
and measured the pressures in the great vessels and cardiac chambers34.This experiment led 
to the first human cardiac catheterization, performed by Werner Forssman on himself in 
192935, which in turn led to the exploration of cardiac hemodynamics by Andre Frederic 
Cournand and Dickinson WW. Richards36. All three of these investigators were awarded the 
Nobel Prize in Physiology or Medicine in 1956. Cardiac catheterization paved the way for the 
development of coronary arteriography in 195837.When combined with ventriculography, it 
allowed clinicians to elucidate the natural history of coronary artery disease. Coronary 
arteriography and left ventriculography became the standard diagnostic tool for defining 
pump function and vessel anatomy and provided the foundation for surgical treatment by 
means of coronary revascularization. The development and refinement of the technique of 
open-heart surgery required close collaborations among surgeons, cardiologists, 
anaesthesiologists, haematologists and engineers38.  The field of invasive cardiology soon 
emerged, built on the pioneering work of Dotter and Judkins, although Andreas Gruntzig is 
considered the father of percutaneous interventional cardiology. The initial technique of 
balloon angioplasty was followed by the insertion of bare metal stents, and today, drug-
eluting stents are used to prevent coronary restenosis39. 
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Modern Therapy 
By the 1970s, in-hospital mortality from acute MI was approximately 15% and in the 
first year after hospital discharge, roughly 10% of patients died from left ventricular failure 
(LVF) associated with large infarctions. Studies in laboratory animals suggested that infarct 
size could be reduced by rectifying the imbalance between myocardial oxygen supply and 
demand40. In 1976, cardiologists opened acutely occluded coronary arteries by intracoronary 
infusion of the fibrinolytic agent streptokinase41. The Italian Group for the Study of 
Streptokinase in Myocardial Infarction (GISSI) trial, one of the first cardiac “mega-trials” 
involving more than 10,000 patients, showed that intravenous streptokinase reduced early 
mortality in patients with acute MI42. The Second International Study of Infarct Survival 
(ISIS-2) showed that the addition of aspirin (an antiplatelet drug) led to further reductions in 
mortality43. Coronary angioplasty and stenting44, together with newer, more potent platelet 
inhibitors (P2Y12 and glycoprotein IIb/IIIa platelet–receptor blockers), further reduced in 
hospital mortality to about 7%. The efficacy of these treatments, including ventricular 
defibrillation, depends on the duration of symptoms and early arrival to the hospital45. 
Since the 1970s, randomized, controlled clinical trials became the paradigm for the 
advancement of clinical cardiovascular therapeutics. The Survival and Ventricular 
Enlargement (SAVE) trial showed that long-term administration of angiotensin-converting–
enzyme inhibitors (ACEI) reduced mortality among patients with left ventricular dysfunction 
after infarction46. The use of beta-adrenergic blockers and aldosterone blockers in these 
patients further reduced mortality. Despite these notable advances, life-threatening heart 
failure still occurs late in patients with extensive ventricular scarring as a consequence of 
large infarcts. Implantable defibrillators47, cardiac resynchronization therapy with 
pacemakers48, and left ventricular assist devices49 have improved the prognosis for such 
patients. Cardiomyocytes from patients with severe heart failure have been found to be 
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deficient in sarcoplasmic reticulumCa2+ ATPase (SERCA2a). In a pilot study, an adeno 
associated virus has been used to deliver the gene for SERCA2a by intracoronary infusion, 
with seemingly beneficial results50. 
 
Unstable Angina and Non ST Segment Elevation Myocardial Infarction 
 
 
In the late 1930s, alert clinicians called attention to what we now refer to as unstable 
angina and non ST segment elevation acute coronary syndrome. Patients with this disorder 
have severe anginal pain, usually at rest, often with biochemical evidence of myonecrosis and 
severe, multivessel, obstructive coronary artery disease. These patients now outnumber those 
with ST-segment elevation myocardial infarction. Patients with non ST segment elevation 
acute coronary syndrome have improvement with prompt coronary revascularization and 
require platelet inhibition with aspirin and a platelet P2Y12-receptor antagonist, together with 
an anticoagulant (low-molecular-weight heparin). Their course after hospital discharge is 
improved by an intensive reduction in low-density lipoprotein (LDL) cholesterol levels51 and 
administration of an anticoagulant52  
Coronary Atherosclerosis 
The ability to access vascular and cardiac tissue rapidly led to the development of 
animal models of vascular disease, as well as clinical studies in humans. Two lines of 
investigation in the 1970s and 1980s forged the field of vascular biology: the observations 
that thrombotic occlusion of a ruptured or eroded atherosclerotic plaque led to acute 
myocardial infarction 53 and that nitric oxide was a physiological dilator of blood vessels, a 
discovery for which Furchgott, Ignarro, and Murad received the 1998 Nobel Prize in 
Physiology or Medicine54-57. This pioneering work transformed our understanding of the 
cellular interactions in both normal and diseased blood vessels and influenced the direction of 
subsequent research. Investigators shifted their attention from animal preparations of intact 
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vessels to molecular and cellular regulation and, ultimately, to the genes that encode the 
growth factors, enzymes, other proteins  and RNAs responsible for the development of 
normal or diseased vessels. 
On the basis of these and other studies, we now understand that atherosclerosis is a 
chronic inflammation of arteries, which develops over decades in response to the biologic 
effects of risk factors.  Atherogenesis begins as a qualitative change to intact endothelial cells 
when subjected to oxidative, hemodynamic, or biochemical stimuli (from smoking, 
hypertension, dyslipidemia) and inflammatory factors, they change their permeability to 
promote the entry and retention of blood-borne monocytes and cholesterol-containing LDL 
particles. Inflammation and biochemical modifications ensue, causing endothelial and 
smooth-muscle cells to proliferate, produce extracellular matrix molecules, and form a 
fibrous cap over the developing atheromatous plaque. Plaques lead to clinical symptoms by 
producing flow-limiting stenoses (causing stable angina) or by provoking thrombi that 
interrupt  blood flow on either a temporary basis (causing unstable angina) or a permanent 
one (causing myocardial infarction). Physical disruption (rupture) of the plaque exposes 
procoagulant material within the core of the plaque to coagulation proteins and platelets, 
triggering thrombosis58.  
Evidence of the causative role of LDL cholesterol in atherosclerosis is threefold: first, 
genetic mutations that impair receptor-mediated removal of LDL cholesterol from plasma 
cause fulminant atherosclerosis; second, animals with low LDL-cholesterol levels have no 
atherosclerosis, whereas increasing these levels experimentally leads to disease; and third, 
human populations with low LDL-cholesterol levels have minimal atherosclerosis, and the  
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process increases in proportion to the level of LDL cholesterol in the blood59,60.  The LDL-
Receptor Pathway and Treatment with LDL Cholesterol–Lowering Drugs, 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins), discovered by Akira 
Endo63, were developed. Brown and Goldstein's discovery of the LDL-receptor pathway61, 
for which they were awarded the 1985 Nobel Prize in Physiology or Medicine, provided a 
genetic cause for myocardial infarction in persons with familial hypercholesterolemia and 
introduced three general concepts to cell biology: receptor-mediated endocytosis, receptor 
recycling, and feedback regulation of receptors. This last concept is the mechanism by which 
statins selectively lower LDL-cholesterol levels in plasma, reducing the risk of myocardial 
infarction and prolonging life, as shown in multiple, definitive clinical trials62,64. 
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 However, statin therapy does not eliminate cardiovascular risk65,66. Levels of high-
density lipoprotein (HDL) cholesterol correlate inversely with cardiovascular risk, but despite 
considerable improvements in our understanding of HDL cholesterol and its metabolism, 
none of the pharmacologic agents that raise HDL cholesterol that have been tested so far have 
had a significant effect on cardiovascular morbidity and mortality. Ongoing clinical trials of 
agents that raise HDL-cholesterol levels and that have other anti-inflammatory and anti-
atherosclerotic effects are currently under way67.  
 
Genomics, Cell-Based Therapies and Molecular Targeting 
 
Genetic investigations have led to discoveries of the heritable components of 
cardiovascular risk factors and coronary artery disease68,69. Multiple chromosomal loci 
associated with CAD harbour protein-coding genes known to be important in variations in 
lipid levels. In addition, associations of single-nucleotide polymorphisms with chemokines 
suggest that an inflammatory pathway may regulate the process of coronary atherosclerosis69.   
Knowledge of molecular pathways is essential to the development of therapeutics, defined 
conceptually as “molecular targeting.” 
Pharmacogenomics applies our understanding of genetic variability in patients' 
responsiveness to a drug in order to inform clinical decisions about dosing and selection. 
Genetic variation in CYP2C9 and VKORC1, the two genes that encode the liver proteins 
required for warfarin metabolism, explains up to 40% of the differences observed among 
patients in their responses to the same dose of warfarin. In patients with genetic variations in 
the cytochrome P-450 enzyme, CYP2C19, the antiplatelet drug clopidogrel is less efficacious 
and the risk of coronary artery disease is increased70.  
Cell-based therapies ranging from autologous noncardiac cells (e.g., bone marrow, 
skeletal muscle, fat, and endothelial progenitors) to allogeneic mesenchymal cells have been 
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studied in preclinical animal models and in early trials in humans, with mixed, yet promising, 
results71-73.A subset of progenitors is mobilized in vivo by paracrine signals in cases of 
cardiac injury, suggesting that the delivery of such signals to the heart or vasculature may 
stimulate regenerative tissue74.  
Global Cardiovascular Disease 
CVDs are no longer confined by geographical area or by age, sex or socioeconomic 
boundaries. Heart disease has already reached epidemic proportions in poorer countries. Of 
the 45.0 million adult deaths reported worldwide in 2002, three-quarters (32 million) were 
due to non communicable diseases (WHO 2003)76. Except in Africa, non communicable 
diseases outnumbered communicable diseases in all WHO regions worldwide. In Southeast 
Asia alone, 7 423 000 deaths were due to non communicable diseases as compared with 5 
730 000 deaths related to communicable diseases in the year 2002. Globally, ischemic heart 
disease (IHD) was the leading killer in the age group  ≥ 60 years, and, with 1 332 000 deaths 
in adults aged 15–59 years, IHD was ranked behind HIV/AIDS only. 
It is well known that the demographic transition in Western countries was 
accompanied by a decrease in deaths due to infectious diseases and increased mortality due to 
noncommunicable diseases. India is in the midst of such demographic transition. The average 
life expectancy at birth in India is 63.7 years, being 63.1 for males and 64.4 for females 77. 
However, this demographic transition has also led to an increase in the number of older 
people (aged ≥60 years), from 19.61 million in 1950 to 75.93 million in 2000 78. The increase 
in life expectancy has brought a large section of the population to an age where CVD starts 
manifesting itself.   
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Cardiovascular disease in India 
In India, CAD rates have increased during the last 30 years, whereas declining trends 
have been noticed in developed Western countries79. Reports on CAD in Indians from 
different parts of the world have shown that Asian Indians are at 3–4 times higher risk of 
CAD than white Americans, 6 times higher than Chinese, and 20 times higher than 
Japanese80-83. The exact prevalence of CAD in India is difficult to estimate owing to the lack 
of a large prospective study. Absence of a centralized death registry for CVDs and 
irregularities in completion of death certificates also hamper estimation of the actual burden 
of CVD84. However, various independent epidemiological studies 85,86conducted in North 
India suggest that the prevalence of CAD has increased from 1% in 1960 to 10.5% in 1998 in 
the urban population. A higher prevalence of CAD, ranging from 11.0% to 14.2%, has been 
reported from South India87-89. In rural India, a twofold increase has been reported in the 
northern states86,90-94. A higher prevalence of 7.4% was observed in some parts of rural South 
India as long ago as in 199395. Taking into account the size of the Indian population, these 
prevalence rates, translated into figures, indicate that a large number of deaths can be 
attributed to CAD. 
Of particular concern to India is not only the high burden of CVDs, but also the 
effects of CVD on the productive workforce aged 35–65 years. The incidence of CAD in the 
young has been reported to be 12%–16% in Indians19,20. Half of the CVD-related deaths 
(52% of CVDs) in India occur below the age of 50 years, and about 25% of acute myocardial 
infarction (MI) in India occurs under the age of 40 years)79,96, a finding similar to that of the 
INTERHEART study22.  Among the three Asian populations, Chinese, Malay, and Indian, the 
highest age-standardized incidence rates in both sexes are in Indians. The first MI attack 
occurs in 4.4% of Asian women and 9.7% of men at age less than 40 years, which is 2- to 3.5 
13 
 
fold higher than in the West European population and is third highest of all the regions 
studied worldwide22. These studies carried out in India and other places suggest that Asians 
in general and Indians in particular are at increased risk of MI at a younger age (<40 years), 
irrespective of whether they have migrated to other countries or are resident Asians. 
 
CREATE Registry 
                 This a large prospective registry study conducted in 89 centres from 10 regions and 50 
cities in India97. 20,937 patients were enrolled. Of the 20,468 patients who were given a 
definite diagnosis, 12 405 (60·6%) had STEMI. The mean age of these patients was 57∙5 
years. Patients with STEMI were younger (56·3 years) than were those with non-STEMI or 
unstable angina (59·3 years). Most patients were from lower middle (52·5%) and poor 
(19·6%) social classes. The median time from symptoms to hospital was 360 min, with 50 
(25–68) minutes from hospital to thrombolysis. 6226 (30·4%) patients had diabetes, 7720 
(37·7%) had hypertension and 8242 (40·2%) were smokers.  
Treatments for STEMI differed from those for non-STEMI or unstable angina. More 
patients with STEMI than with non-STEMI were given anti-platelet drugs (98·2% vs. 97·4%), 
angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB) 
(60·5% vs. 51·2%), and percutaneous coronary interventions (8·0% vs. 6·7%). Thrombolytics 
(96·3% streptokinase) were used for 58·5% of patients with STEMI. Conversely, fewer 
patients with STEMI than those with non-STEMI or unstable angina were given β blockers 
(57·5% vs 61·9%), lipid-lowering drugs (50·8% vs 53·9%) and coronary bypass graft surgery 
(1·9% vs 4·4%).  
The 30-day outcomes for patients with STEMI were death (8·6%), reinfarction 
(2·3%), and stroke (0·7%). Outcomes for those with non-STEMI or unstable angina were 
better: death (3·7%), reinfarction (1·2%) and stroke (0·3%). Use of key treatments also 
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differed by socioeconomic status. More rich patients than poor patients were given 
thrombolytics (60·6% vs 52·3%), β blockers (58·8% vs 49·6%), lipid-lowering drugs (61·2% 
vs 36·0%), ACE inhibitors or ARB (63·2% vs 54·1%), percutaneous coronary intervention 
(15·3% vs 2·0%) and coronary artery bypass graft surgery (7·5% vs 0·7%). Mortality was 
higher for poor patients than for rich patients (8·2% vs 5·5%)97. Adjustment for treatments 
(but not risk factors and baseline characteristics) eliminated this difference in mortality. 
 
Risk factors of premature CAD in Indians 
Most of the knowledge on CAD risk factors in different age groups is from studies 
carried out in the migrant Indian population98-101, and these have their limitations. It has been 
suggested that the results of these studies cannot be generalized, as there is either over 
representation of certain communities or under-representation or absence of other 
communities. 
            Heart diseases are occurring in Indians 5 to 10 years earlier than in other populations 
around the world80,102. According to the INTERHEART study22, the median age for first 
presentation of acute MI in the South Asian (Bangladesh, India, Nepal, Pakistan, Sri Lanka) 
population is 53 years, whereas that in Western Europe, China, and Hong Kong is 63 years, 
with more men than women affected. Data from the Singapore Myocardial Infarction 
Registry from 1988 to 1997 for acute MI cases aged between 20 and 64 years also showed 
that men were four times more prone to these events than women. The median age for 
presentation of first MI was higher in Asian women than in Asian men (58 and 54 years, 
respectively), a finding similar to that of the INTERHEART study22.  It must be emphasized 
that although the median age of presentation is higher in women, they are known worldwide 
to have poor prognosis compared with men103-107. Younger Asian women have worse survival 
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at 28 days after acute MI. The reasons for higher mortality in younger women are poorly 
understood and may be related to the presence of different risk factors in women, co 
morbidities, severity of infarction, and response to treatment. In view of the above discussion, 
it is imperative to ascertain the causes of the rising prevalence and emergence of CAD earlier 
in the life of Indians. 
The INTERHEART study22, involving 52 countries, established an association 
between conventional modifiable risk factors for MI in all regions of the world, including 
South Asia, and in both sexes and at all ages. In South Asians, apolipoprotein (Apo)B/ApoA1 
(odds ratio [OR] 3.81) and smoking (OR 2.43) were the important risk factors, as in the rest 
of the world. However, hypertension (OR 2.89), abdominal obesity (OR 2.43), and diabetes 
(OR 2.48) had more severe effects in South Asia, whereas psychosocial factors had an odds 
ratio of 2.15, compared with 2.67 worldwide. The INTERHEART study22 also showed that 
hypertension and diabetes were more important risk factors in younger Indian women than 
men. Earlier studies, mostly in Western populations, have also found an association of the 
above-mentioned risk factors with the development of CAD. For example, in the Prospective 
Cardiovascular Munster Heart Study (PROCAM), a large prospective study in men aged 35–
65 years, eight variables that made an independent contribution to risk of CAD were age, 
systolic blood pressure, LDL-C, HDL-C, triglycerides, diabetes mellitus, smoking and family 
history of MI108. The Jaipur Heart Watch-2 study is a prospective study from North India that 
found a high prevalence of classical risk factors for CAD, namely smoking, low physical 
activity, hypertension, hypercholesterolemia, diabetes, and obesity in urban men and women 
of Jaipur109. Factors peculiar to the South Asian population, such as truncal obesity, low 
HDL-C, and high triglycerides, were also prevalent. A significant increase in people with 
obesity, diabetes, and dyslipidemia was observed as compared with those reported in the 
Jaipur Heart Watch-1 study carried out in the early 1990s in the same population. An 
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increasing prevalence of impaired glucose tolerance and diabetes in urban residents of 
Chennai has also been reported110. Fewer studies on epidemiological data from 
angiographically proven cases of premature CAD (≤40 years) in native Indians are 
available111-117. Hyperlipidemia was found to be prevalent in young Indians with CAD in 
these studies. However, differences appear to exist between the lipid levels present in North 
and South Indian CAD patients and individuals without CAD. It appears that North Indians 
manifest the disease at lower levels of total cholesterol. Also, a greater role can be attributed 
to total cholesterol and LDL-C in atherogenesis in the younger Indian population (≤40 years) 
with angiographically proven CAD. The lower HDL-C and higher triglyceride levels in both 
younger and older cases appear to be a hallmark of the Indian population89,117. In the 
INTERHEART study22 also, the highest population attributable risk (PAR) was abnormal 
lipids (ApoB/ApoA1 ratio) in both sexes. These studies indicate that abnormalities in lipid 
metabolism play an important role in development of CAD in young Indians. Also, compared 
with women113, young Indian male patients have a slightly lower prevalence of hypertension 
and diabetes,112,117. 
Smoking and low physical activity in Indians have been found to be prevalent among 
20–39 years old urban adults109. The INTERHEART study22 also observed that smoking was 
a greater risk factor in younger men than in women. The risk of CAD increased incrementally 
with smoking. The odds ratio was 9.16 in individuals who smoked more than 40 cigarettes 
per day, compared with 1.38 in those smoking 1–5 cigarettes per day, indicating that there is 
no safe limit for smoking. Other epidemiological studies from India also suggest a greater 
association of smoking with CAD in younger individuals114,117. Furthermore, the prevalence 
of smoking in South Indian males (44.6%) and passive smoking in South Indian females 
(45.3%) has been reported to be significantly higher than in North Indians87. Interestingly, 
smoking has not been found to be a significant risk factor in acute MI patients from rural 
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parts of India. The patients from rural India, however, have elevated blood glucose and 
abnormal waist/hip ratio118. 
Another important independent risk factor for CAD in younger cases emerging out of 
Indian studies is family history of CAD111-114. The INTERHEART study22 showed a 
population attributable risk (PAR) of 14.8% in younger versus 10.45% in older patients. 
Though addition of family history of CAD to other risk factors causes only a modest increase 
in PAR by 1%, it must be emphasized that modifiable physiological variables such as blood 
pressure, ApoB/ApoA1 ratio, serum cholesterol, and abdominal obesity are also partially 
under genetic control. As family history of CAD emerged as the second most important risk 
factor in young Indian patients117, analysis of potential genetic factors such as variance of 
genes involved in vascular homeostasis, hemostatic factors, lipid metabolism, and other 
metabolic factors is warranted. 
Evidence from studies carried out in South Asians suggests that conventional risk 
factors account for 90% of the PAR in men and 94% in women (hypertension, smoking, 
diabetes, ApoB/ApoA1 ratio and abdominal obesity accounted for 80.2% of the PAR). As 
these risk factors were also established by Indian studies to be involved in premature CAD, 
there are now enough data for establishment of health policies to counteract the threat posed 
by the epidemic of CVDs in India. Modification of environmental triggers for these risk 
factors is likely to reduce the speed of this advancing epidemic. The benefits of genetic 
research in this area can in future be reaped in economic terms. 
 
Diabetes Mellitus and CAD 
           Diabetes mellitus is a group of diseases characterized by insufficient production of 
insulin or by the failure to respond appropriately to insulin, resulting in hyperglycemia. The 
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diagnostic criteria are summarized in Table 1.122 Importantly, new to the diagnostic criteria in 
2010, a glycosylated hemoglobin (A1c) level ≥6.5% has been added. Diabetes is typically 
classified as type 2 diabetes, characterized by relative insulin deficiency with a backdrop of 
insulin resistance and representing >90% of all diabetes cases, or type 1 diabetes, 
characterized by absolute insulin deficiency.  
             Diabetes is among the most common chronic diseases in the world, affecting an 
estimated 180 million people in 2008.123 Confounding this high global burden is the 
increasing incidence and prevalence of type 2 diabetes, driven by increasing population age, 
obesity and physical inactivity as well as by the increasing longevity of patients with 
diabetes. Estimates project that more than 360 million persons will be affected by diabetes by 
2030. 
Table 1.   American Diabetes Association Diagnostic Criteria for Diabetes Mellitus122 
    Fasting plasma glucose ≥ 7.0 mmol/liter (126 mg/dL) 
    or  
   
 2-hour plasma glucose ≥ 11.1 mmol/liter (200 mg/dL) during standardized 75-g oral 
glucose tolerance test 
    or  
    Symptoms of hyperglycemia plus nonfasting plasma glucose ≥ 11.1 mmol/liter 
    or  
    A1c ≥ 6.5% (200 mg/dL) 
 
Whereas much attention historically has focused on the prevention and treatment of 
microvascular disease complications of diabetes, cardiovascular disease (CVD) remains the 
principal morbidity and driver of mortality in the setting of diabetes, most commonly in the 
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form of coronary heart disease (CHD), cerebrovascular disease, peripheral vascular disease, 
and heart failure. For these reasons, continual efforts toward mitigating the risk of CVD in 
diabetes remain a global public health imperative. 
Compared with nondiabetic individuals, patients with diabetes have a 2-4 times 
increased risk for development and dying of CHD124. Whereas older studies have suggested a 
diabetes associated CVD risk similar to that observed among nondiabetic patients with MI, 
that is, a “coronary disease equivalent”, more recent observations from clinical trials suggest 
a substantially lower CHD risk, most likely reflecting the effectiveness of contemporary 
therapeutic interventions.125-7 
 Diabetes is associated with an increased risk for MI. Across the spectrum of ACS 
events, in which diabetes may affect more than one third of patients,128 patients with diabetes 
have worse CVD outcomes.129 Despite overall improvements in outcomes during the past 
several decades for ACS, the gradient of risk associated with diabetes persists.129 
Furthermore, the increased risk observed with diabetes in the setting of ACS events extends 
to glucose values in the range well below the diabetes threshold, whether it is analyzed by 
glucose values at the time of presentation or those observed throughout hospitalization.130 
Compared with nondiabetics, diabetic patients have a greater atherosclerotic burden, both in 
the major arteries and in microvasculature. Diabetic patients have substantially increased 
rates of atherosclerotic complications in the settings of primary prevention and after coronary 
intervention procedures. 
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Prediabetes and CAD 
                     Almost 35 million Americans have some degree of abnormal glucose tolerance, 
a condition along with obesity that markedly increases the risk for type 2 diabetes and 
premature atherothrombosis. Insulin resistance alone confers an elevated risk of heart failure 
and probably explains the association of obesity with this diagnosis.131 Moreover, the risk of 
cardiovascular disease starts to increase long before the onset of clinical diabetes. In the 
Nurses Health Study, women who eventually developed type 2 diabetes had a threefold 
elevated relative risk of myocardial infarction before the diagnosis of diabetes, a 
cardiovascular event rate almost as high as that in patients with overt diabetes at study 
entry.132 These effects are magnified in ethnic minority populations and in patients with other 
concomitant risk factors. 
Although hyperglycemia associates with microvascular disease, insulin resistance 
itself promotes atherosclerosis even before it produces frank diabetes, and available data 
corroborate the role of insulin resistance as an independent risk factor for atherothrombosis.             
This finding has prompted recommendations for increased surveillance for the metabolic 
syndrome, a cluster of glucose intolerance and hyperinsulinemia accompanied by 
hypertriglyceridemia, low HDL levels, hypofibrinolysis, hypertension, microalbuminuria,  
predominance of small, dense LDL particles, and central obesity.  
Although several formal definitions of the metabolic syndrome have been proposed, 
the definition adopted by the National Cholesterol Education Program Adult Treatment Panel 
requires at least three of the following five criteria:  
1. Waist circumference larger than 102 cm in men and 88 cm in women 
2 .Serum triglyceride levels of at least 150 mg/Dl 
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3. HDL cholesterol less than 40 mg/dL in men and less than 50 mg/dL in women 
4. Blood pressure of at least 130/85 mm Hg 
5.Serum glucose concentration of at least 110 mg/dL.  
 
                    Table 2. Mechanisms Implicated in Diabetic Vascular Disease 
Endothelium 
    ↑ NF-κβ activation 
    ↓ Nitric oxide production 
    ↓ Prostacyclin bioavailability 
    ↑ Endothelin 1 activity 
    ↑ Angiotensin II activity 
    ↑ Cyclooxygenase 2 activity 
    ↑ Thromboxane A2 activity 
    ↑ Reactive oxygen species 
    ↑ Lipid peroxidation products 
    ↓ Endothelium-dependent relaxation 
    ↑ RAGE expression 
 
Vascular smooth muscle cells and vascular 
matrix 
   
 ↑ Proliferation and migration into 
intima 
    ↑ Increased matrix degradation 
    Altered matrix components 
 
Inflammation 
    ↑ IL-1β, IL-6, CD36, MCP-1 
    ↑ ICAMs, VCAMs, and selectins 
    ↑ Activity of protein kinase C 
    ↑ AGEs and AGE/RAGE  
 
AGEs - advanced glycation end products; ICAMs - intracellular adhesion molecules; IL -
interleukin; MCP - monocyte chemoattractant protein; NF - nuclear factor; RAGE - receptor 
for advanced glycation end products; VCAMs - vascular cell adhesion molecules. 
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Hyperglycemia is likely to directly influence atherosclerosis development, 
progression, and instability. The principal vascular perturbations linked to hyperglycemia 
include endothelial dysfunction, vascular effects of advanced glycation end products, adverse 
effects of circulating free fatty acids, and increased systemic inflammation. In addition, the 
pernicious effects of hypoglycemia complicating diabetes therapy, the sympathovagal 
imbalance due to diabetic autonomic neuropathy, and the vascular effects of constitutive 
exposure to excess insulin may further contribute to atherosclerotic risk. 
Endothelial dysfunction, a hallmark of diabetic vascular disease, is associated with 
increased hypertension and adverse CVD outcomes. The myriad mechanisms contributing to 
endothelial dysfunction include abnormal nitric oxide biology, increased endothelin and 
angiotensin II, and reduced prostacyclin activity, all of which contribute to abnormal control 
of blood flow. In the setting of ACS events, no-reflow after percutaneous intervention 
reflecting acute endothelial dysfunction occurs more commonly in the presence of diabetes or 
hyperglycemia and may contribute to increased myocardial jeopardy, resulting in larger 
infarcts, increased arrhythmia, and worse systolic function. 
Diabetic dyslipidemia is characterized by high triglyceride levels, low HDL and 
increased atherogenic small dense LDL particles, each of which is likely to contribute to the 
accelerated development and progression of atherosclerosis. Perturbations in the fibrinolytic 
system and platelet biology further compound the direct vascular effects of diabetes, yielding 
a constitutive prothrombotic milieu. These abnormalities include increased circulating tissue 
factor, factor VII, von Willebrand factor, and plasminogen activator inhibitor 1, with 
decreased levels of antithrombin III and protein C. In addition, disturbances of platelet 
activation, aggregation, morphology and life span further contribute to increased thrombotic 
potential, as well as to the acceleration of atherosclerosis. 
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     Table 3. Perturbations of Platelet Function Associated with Diabetes 
 
    Reduced membrane fluidity 
    Altered Ca2+ and Mg2+ homeostasis 
    Increased arachidonic acid metabolism 
    Increased thromboxane A2 synthesis 
    Decreased nitric oxide and prostacyclin production 
    Decreased antioxidant levels 
   
 Increased expression of activation-dependent adhesion molecules (e.g., glycoprotein 
IIb/IIIa, P-selectin) 
    Increased platelet micro particle formation 
    Increased platelet turnover 
 
 
 Increased systemic inflammation portends an increased risk for diabetes and diabetic 
atherosclerotic disease, and diabetes is associated with increased oxidative stress and the 
accumulation of advanced glycation end products. Diabetes is associated with lipid-rich 
atherosclerotic plaque and increased inflammatory cell infiltration, increased expression of 
tissue factor, and increased expression of the receptor for advanced glycation end products, 
yielding plaques with characteristics of higher risk in both coronary and carotid arteries. 
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Prediabetes and CAD -Evidence 
           A meta-analysis133 showed that the estimated relative risk (RR) for cardiovascular 
disease associated with impaired glucose tolerance (IGT) ranges from 0.97 to1.30 and that 
associated with impaired fasting glucose (IFG) ranges from approximately1.12 to 1.37. 
Furthermore, the risk associated with IFG 110 mg/dl was larger than that for IFG 100 mg/dl. 
At present, the available data are insufficient to confirm the presence of sex difference in the 
risk between pre-diabetes and cardiovascular disease. 
                  Some reviews have suggested that IGT increased the risk for macrovascular 
disease by approximately 2-fold.   Subsequent studies that were based on the 1980 or 1985 
WHO criteria in which IGT was defined as a fasting plasma concentration of glucose of 140 
mg/dl and a 2-h concentration of glucose of 140 to 200 mg/dl also reported an approximate 
doubling of risk for cardiovascular disease among participants with IGT. Although more data 
were available for IFG 110 mg/dl than for IFG 100 mg/dl, the number of such studies was 
still limited.   
                  Regarding IGT, there are currently insufficient data to arrive at a conclusion 
concerning potential sex differences. Of note is the finding from the DECODE study in 2001 
that the RRs for cardiovascular disease among participants with 2-h glucose abnormalities 
corresponding to IGT were very similar for men and women134. It is not clearly known 
whether the risk for developing cardiovascular disease is present for people with pre-diabetes 
even if they never develop diabetes. At least 2 attempts have been made to address this issue 
and have failed to produce definitive insights into this issue135.  
                   Current recommendations to screen for Prediabetes are inconsistent. The U.S. 
Preventive Services Task Force does not support screening for pre-diabetes, whereas the 
ADA supports screening among people at increased risk on the basis of age and body mass 
index. Nevertheless, an economic analysis that incorporates the prevention of CVD might 
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provide additional useful information concerning the need to screen for pre-diabetes in the 
general population or in specific population groups at high risk. 
In summary, the exact magnitude of the risk for CVD associated with IFG or IGT 
remains opaque at present. Depending on the set of studies examined, analyses could be 
interpreted as implying no increase in risk or at most a very modest increase in risk. Given 
the sizeable and growing percentage of adults who have pre-diabetes in some countries like 
the United States, South Asia, a small increase in risk might still translate into substantial 
numbers of adults developing or dying from cardiovascular disease. 
  
Prediabetes in India 
The metabolic syndrome (MS) is common among South Asians. The term South 
Asian refers to all individuals who have ancestral origin in the Indian subcontinent (India, 
Pakistan, Bangladesh, Nepal, and Srilanka). Because South Asians develop metabolic 
abnormalities at a lower body mass index (BMI) and waist circumference(WC) than other 
groups, conventional criteria underestimate the prevalence of MS by 25% to 50%. The South 
Asian Modified National Cholesterol Education Program criteria that use abdominal obesity 
as an optional component and the South Asian specific waist circumference recommended by 
the International Diabetes Federation appear to be more appropriate in this population. 
Furthermore, Asian Indians have at least double the risk of CAD than that of whites, even 
when adjusted for the presence of diabetes and MS. This increased risk appears to be due to 
South Asian dyslipidemia, which is characterized by high serum levels of apolipoprotein B, 
lipoprotein (a), triglycerides and low levels of apolipoprotein A1 and HDL cholesterol. In 
addition, the LDL particles are small, dense, and dysfunctional. MS needs to be recognized as 
a looming danger to South Asians and treated with aggressive lifestyle modifications 
beginning in childhood and at a lower threshold than in other populations.  
26 
 
Asian Indian or South Asian Phenotype 
 Many Asian Indians fit into the model of metabolically obese, normal weight 
individuals.136 This group comprises only 6% of all whites but a substantial segment of Asian 
Indians.137 Many Asian Indians develop diabetes and MS with a BMI <25 kg/m2, which is 
generally considered normal among whites. South Asians, in general, and Asian Indians, 
in particular, have certain unique clinical and biochemical characteristics that are collectively 
referred to as the “South Asian” or “Asian Indian”phenotype. Compared with whites at 
comparable BMI and age, Asian Indians have profoundly higher dyslipidemia, and 
hypoadiponectinemia, greater WC, thinner hips, short legs and increased cardiovascular 
risk138. For any given WC, they also have increased visceral fat and insulin resistance that are 
evident even among children aged 8 to 11 years139. For example, South Asian children with a 
WC of 80 cm have higher insulin levels than white children with a WC of 90 cm. In addition, 
South Asians also have significant procoagulant tendencies as shown by high plasminogen 
activator inhibitor-1and fibrinogen concentrations.140 These metabolic abnormalities also 
contribute to the increased predilection for diabetes and CAD.  
 
Differing Criteria for Obesity and Abdominal Obesity among Asians 
Because of the above mentioned observations, The World Health Organization(WHO) 
has issued a lower cut-off point for overweight (BMI >23) and obesity (BMI >25) for all 
Asians.141 By this criterion, 95% of South Asian diabetic patients were identified as 
overweight and 80% were obese in the United Kingdom Asian Diabetes Study(UKADS)142. 
A more recent study found WC of 87 cm for men and 82 cm for women as appropriate cut-
off points to identify cardio metabolic risk factors including prediabetes in urban Asian 
Indians143.35 The WHO and IDF have also issued lower cut-off points for WC for the 
diagnosis of abdominal obesity for South Asian men (90 cm) and women (80 cm)144.  
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South Asian Modified NCEP Criteria for MS 
Although NCEP does not provide ethnic-specific cut-off points for waist 
circumference (WC), the 2005 AHA/NHLBI Scientific Statement on MS endorses the lower 
WC for all Asian Americans (<90 cm for men and <80cm for women).145 The South Asian 
Modified(SAM) NCEP Criteria follows the NCEP criteria for MS except for the inclusion of 
South Asian specific WC cut-off points for abdominal obesity as recommended by the 
IDF.145-6 Thus, unlike the IDF criteria, abdominal obesity is considered optional, not essential. 
Among South Asians, the prevalence of MS is higher by 30% to 50% when SAM-NCEP 
criteria are applied compared with NCEP criteria and 20% higher compared with IDF criteria. 
Clinical diabetes and CAD are preceded by a constellation of risk factors that are also the 
components of MS, the prevalence of which among Asian Indians is approximately 25% with 
either NCEP or IDF criteria. The prevalence increases to 35% to 40% when the SAM–NCEP 
criteria are used. The prevalence of MS among South Asians is higher than in other Asians 
and Europeans. The syndrome confers a 2-fold risk of CAD and a 5-fold risk of diabetes.  
Primary treatment of MS is lifestyle therapy and includes weight loss, increased 
physical activity, and an antiatherogenic diet. Adopting a healthy lifestyle beginning in 
childhood and adolescence is warranted in view of the malignant nature of CAD among 
Asian Indians. Because the adverse effects of these factors are greater in Indians, the benefits 
of modifying the factors are correspondingly greater and may prevent the onset of diabetes. 
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AIMS OF THE STUDY 
  The primary aims of the study are to analyze  
1. The prevalence of Conventional risk factors among patients who present with 
Myocardial infarction at young age. 
2. The demographic profile of patients.  
3. The prevalence of Hyperhomocysteinemia and high hemoglobin. 
The secondary aims of the study are 
1. To analyze the mode of presentation.  
2. To analyze the profile of coronary lesions in angiogram.  
3. To assess the prevalence of LV dysfunction.  
 
 
 
 
 
 
 
 
 
  
 
 
                MATERIALS AND                                            
                             METHODS 
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 MATERIALS AND METHODS 
This is a prospective observational study of young patients admitted with a diagnosis 
of myocardial infarction to our Intensive Coronary Care Unit and evaluated.  
Young patients with age 40 years or less were included in the study. Most similar 
studies of premature CAD have used an age cut-off of 40 to 45 years to define "young" 
patients with CAD and AMI.1-5. The study was conducted over a period of one year from 1st 
October 2010 to 30th September 2011. All consecutive patients admitted with Acute coronary 
syndromes (ACS), both STEMI and NSTEMI as per standard definition during this period 
were included in the study after consent.  The study was conducted at PSG hospitals, the 
teaching affiliate of PSG institute of Medical Sciences and research (PSG IMS & R) which is 
a teaching and tertiary care referral hospital located in the city of Coimbatore. Patients are 
from the city as well as from nearby towns, villages and a few from the adjoining state of 
Kerala.  
The patients who did not get the complete evaluation including coronary angiogram 
for various reasons were excluded from the study. 
The purpose of the study was explained to the patients and relatives and consent was 
obtained. The study was approved by the Human Ethics Committee of the institution before 
commencement of the study. 
 The Inclusion criteria were 
1. Age   less than or equal to 40 years. 
2. Both male and female patients.  
3. Typical chest pain suggestive of AMI.  
4. ST elevation in ECG as per definition at the time of presentation with chest pain 
          ( STEMI ) 
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5.  Positive Troponin T (NSTEMI) 
Exclusion criteria: 
1. Age > 40 years. 
2. Non cardiac chest pain. 
3. Patients who did not get admitted. 
4. Patients who did not undergo coronary angiogram. 
             All Patients’ demographic profile, income and marital status were noted at the time 
of admission.  
Patients were enquired for standard history of hypertension, diabetes mellitus, 
dyslipidemia, smoking, alcohol consumption and family history of Coronary Artery 
Disease.  
Blood investigations at the time of admission included complete blood count, fasting 
lipid profile, Hb A1c. 
Patients were labeled as hypertensive if they have been documented to have high 
Blood Pressure during previous medical consultations, if they are on antihypertensive 
medications, or if their BP is   ≥ 140/90 consistently during current admission. 
Patients were labeled as diabetic if they have documented fasting blood sugar of 127 
mg/dl or Hb A1c  of  > 6.5 gm% or if the same is noted during current admission. Fasting 
serum Homocysteine level and hemoglobin levels were checked in all patients. 
All patients underwent transthoracic 2D and Doppler echocardiogram with colour 
Doppler study. LV systolic and diastolic function were routinely assessed. Mechanical 
complications like Mitral regurgitation, ventricular septal rupture, free wall rupture and 
pericardial effusion were also looked for.  
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Patients underwent treatment modalities of Thrombolysis, Primary Percutaneous 
Coronary Intervention (PCI) or conservative management as feasible and required, 
depending on the clinical circumstances and consent at the time of presentation. All 
patients were treated with dual antiplatelets, atorvastatin, low molecular weight heparin 
and other indicated drugs as per standard protocols.  
All patients underwent coronary angiogram either at the time of admission for 
primary PCI or electively after initial medical stabilization with Thrombolysis or 
conservative treatment. Presence of coronary lesion, type of lesion, presence or absence of 
thrombosis, myocardial bridging, coronary anomalies and ectasia were looked for. 
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RESULTS AND ANALYSIS  
 
             69 PATIENTS WERE INCLUDED FOR THE STUDY BASED ON THE 
ENTRY CRITERION.  
Age 
         Among the 69 patients studied, 6 patients were under the age of 30 years (8.7%). 
Remaining 63 years patients were between 31-40 years of age (91.3%). 
Sex  
         60 Patient were Males (86.95 %), 9 patients were Females (13.05 %), which is 
statistically significant. 63  Patients (91.3%) were married. 6 patients (8.7%) were unmarried. 
.  
 
                       Bar diagram showing proportion of male and female patients 
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Demographic profile         
         When residence of the patients was analyzed, 26 patients (37.7%) came from 
corporation (Cities, Big towns), 22 patients (31.9%) came from municipalities and 21 patients 
(30.4%) came from villages.  
 
 
 
         According to income, patients were divided into four groups. 32 patients (46.42%) were 
earning less than Rs. 72000 per annum, 24 patients [34.8 %] were earning between Rs.72000-
2,00,000,  6 patients  (8.7%) were earning  Rs.2,00,000- 4,00,000  and  7 Patients (10.1%) 
were earning  > Rs. 4,00,000 per annum.  
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Conventional risk factors  
1. Hypertension was present in 15 patients (21.7%).  
2. 17 Patient (24.6%) were diabetics, among whom 2 of them were Insulin requiring.  
3. 20 Patient (29 %) had history of dyslipidemia.  
4. 37 patients (53.6%) were current smokers or have been smoking in the recent past.  
5. 8 patients (11.6%) had family H/o Coronary artery disease.  
6. 21 patients (30.4%) were consuming alcohol on a regular basis.  
7. 5 patients (7.2%) had obesity based on BMI.  
8. Patients were labeled as having pre diabetes if their HbA1C is between 5.5 and 6.4 
in the absence of documented Diabetes mellitus in the past.  34 patients (49.27%) 
had prediabetes. 20 patients (28.98%) had HbA1C < 5.5 gm%, 15 patients 
(21.75%) had HbA1C > 6.5 gm% . 
Lipid profile  
           All patients had fasting lipid profile done during admission within 48 hours.  
1. 54 Patients (78.26%) had LDL cholesterol > 100mg%.  
2. 53 Patients (76.82 %0 had HDL< 40mg %. 
3. 35 Patients (50.72%) had TGL level > 150%. 
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Other factors 
1. Vasculitis :   2 patients (2.9%) had H/o symptoms  of suggestive of vasculitis, both of 
whom are female patients. 
2. High Hemoglobin : Hemoglobin was checked in all patients. 13 patients (18.84%) 
had Hb <13, among whom 2 patients (2.9%) had Hb < 10 gm%.  5 patients (7.25%) 
had Hb  > 17gm%.  
3. Hyperhomocysteinemia: 13 patients(18.8 %) had hyperhomocysteinemia whose 
levels were from 15 to more than 50 micromol/lit. 
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Mode of presentation  
          According to ECG analysis, 50 patients (72.5%) had STEMI, 19 patients (27.5 %) had 
NSTEMI.  
Left ventricular function 
          All patients underwent transthoracic echocardiogram.  Mild LV dysfunction is defined 
as EF 40- 49 %, moderate LV dysfunction as EF 30-39 %, severe LV dysfunction as < 30 %.  
Majority, 54 patients (78.25%) had normal LV function. 13 patients (18.95%) had mild LV 
dysfunction, 2 patients (2.9%) had moderate LV dysfunction (EF 31-45%). None of them had 
severe LV dysfunction.   
Complications  
1. 3 patients (4.3%) presented with recurrent MI.  
2. 2 patients (2.9%) developed arrhythmias both of which were ventricular 
arrhythmias. 
3. None of them developed Pericardial effusion or any significant mechanical 
complications. 
4.  None of them had atrial fibrillation.  
5. No incidence of cerebrovascular accident was observed. 
6. None of the patients died during the index admission. 
Treatment  
      Among the 50 patients who had STEMI, 22 patients underwent thrombolysis with 
streptokinase (44 %) and 13 patients (26 %) underwent primary PCI. 15 patients (30 %) were 
treated conservatively with conventional treatment.  
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Coronary angiogram     
      Analysis of coronary angiogram showed 
1. Single vessel disease in 43 patients [ 62.32 %] 
2. Double vessel disease in 7 patients [10.15 %] 
3. Triple vessel disease in 7 patients [ 10.15 %] 
4. Recanalised vessels in 12 patients [17.4 %] 
5. Thrombus was seen in 26 patients [37.68%].   
6. Collateral vessels, bifurcation lesion, coronary ectasia were seen in one patient each. 
 
 
               Among the single vessel disease patients, Left Anterior Descending artery or its 
major branch involvement was the most common presentation seen in 33 patients (47.8 %) 
followed by right coronary artery involvement in 6 patients (8.7 %).  Left Circumflex artery 
was the least common infarct related artery, seen in 4 patients (5.8 %). 
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Residence based analysis: 
 Urban Rural 
Total  48 [69.56 %] 21 [30.44 %] 
Hypertension  9 [ 18.8 %] 6 [28.6 %] 
Diabetes  14 [ 29.2 %] 3 [ 14.3 %] 
Prediabetes  20[ 41.6 %] 12[ 57.2 %] 
H/o Dyslipidemia  14 [ 29.2 %] 6 [ 28.6 %] 
Smoking  19 [ 39.6 %] 18 [ 85.7 %] 
Positive Family history 5 [ 10.4 %] 3[14.3 %] 
Vasculitis  2 0 
Alcohol consumption 16 [ 33.3 %] 5[ 23.8 %] 
hyperhomocysteinemia 9[18.8 %] 4[ 19 %] 
LDL > 100 mg % 38 [ 79.2 %] 5[23.8 %] 
HDL < 40 mg % 37[ 77 %] 16 [ 76.2 %] 
TGL > 150 mg % 26[ 54.2 %] 9[42.9 %] 
Hb > 17 gm % 4[8.3 %] 1 [ 4.8 %] 
LV Dysfunction [EF < 50 %] 11[22.9 %] 4[ 19 %] 
Recurrent MI 3 [6.2 %] 0 
Arrythmias 2 [ 4.2 % ] 0 
STEMI 36[75 %] 14[66.6 %] 
NSTEMI 12[25 %] 7[33.3 %] 
Thrombolysis  15[41.66 %] 7[ 50 %] 
Primary PCI 12[ 33.3 %] 1[7.14 %] 
 
          When urban and rural patients were compared, urban patients had higher incidence of 
diabetes(29.2% vs 14.3%), increased LDL(79.2 % VS 23.8 %). Rural patients had higher 
incidence of hypertension (28.6 % vs 18.8 %), smoking (85.7 % vs 39.6 %). Urban patients 
underwent primary PCI more frequently than rural patients (33.3 % vs 7.14 %). 
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Income based analysis 
 LOW INCOME MODERATE 
INCOME 
HIGH INCOME 
Total  33 29 7 
Hypertension  4[12.1%] 8[27.6%] 3[ 42.9 %] 
Diabetes  7[ 21.2 %] 9[ 31 %] 1[ 14.9 %] 
Prediabetes  16[48.5 %] 15[51.7 %] 3[42.9 %] 
Dyslipidemia  7[21.2 %] 10[34.5 %] 3[ 42.9 %] 
smoking 17[51.5 %] 15[ 51.7 %] 5[ 71.4 %] 
Positive FH 6[3.4 %] 1[14.3 %] 1[ 11.6 %] 
Alcohol 4[12.1 %] 8[27.6 %] 3[42.9 %] 
hyperhomocysteinemia 9[27.3 %] 3[10.3 %] 1[14.3 %] 
LDL > 100 mg % 25[ 75.8 %] 23[79.3 %] 6[ 85.7 %] 
HDL < 40 mg % 25[ 75.8 %] 22[ 75.9 %] 6[85.7 %] 
TGL >150 mg % 15[ 45.5 %] 17[58.6 %] 3[42.9 %] 
EF < 50 % 7 [ 21.2 %] 7[ 24.1 %] 1[14.3 %] 
RECURRENT MI 1[3 %] 2[6.9 %] 0 
Arrhythmias  2[6.1 %] 0 0 
STEMI 23[69.7 %] 21[72.4 %] 6[85.7%] 
NSTEMI 10[30.3 %] 8[27.6 %] 1[14.3 %] 
Thrombolysis  12[52.2 %] 9[42.9 %] 1[16.6 %] 
Primary PCI 5[21.7 %] 5[23.8 %] 3[50 %] 
Conservative  6[26.1 %] 7[33.3 %] 2[33.3 %] 
 
         Incidence of Prediabetes is high irrespective of the income of the patients, which is 48.5 
%, 51.7 %, 42.9 % in low, moderate, high income patients respectively. Incidence of 
dyslipidemia is also equally high among patients with various income. High income patients 
underwent primary PCI more frequently [50 %].  
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Gender Based Analysis 
 MALE FEMALE 
Total  60 9 
Hypertension  14[23.3%] 1[11.1%] 
Diabetes  14[ 23.3 %] 3[ 33.3 %] 
Prediabetes  29[48.3 %] 5[55.6 %] 
Dyslipidemia  19[31.7 %] 1[11.1 %] 
smoking 36[60 %] 0 
Positive FH 8[13.3 %] 0 
Alcohol 21[35.0 %] 0 
hyperhomocysteinemia 13[21.7 %] 0 
LDL > 100 mg % 47[ 78.3 %] 7[77.8 %] 
HDL < 40 mg % 48[ 80 %] 5[55.6 %] 
TGL >150 mg % 31[51.7 %] 4[44.4 %] 
Hb > 17 gms % 5[ 8.3 %] 0 
EF < 50 % 13 [ 21.7 %] 2[ 22.2 %] 
STEMI 43[71.7 %] 7[77.8 %] 
NSTEMI 17[ 28.3 %] 2[22.2 %] 
RECURRENT MI 2[3.3 %] 1[11.1 %] 
Arrhythmias  2[3.3 %] 0 
Thrombolysis  9[20.9 %] 3[42.85 %] 
Primary PCI 12[27.9 %] 1[14.3 %] 
Conservative  22[51.2 %] 3[42.85 %] 
Vasculitis 0 2[22.2 %] 
 
Gender based analysis showed 
1. Higher incidence of hypertension among male patients(23.3 % vs 11.1 %) 
2. Higher incidence of diabetes among female patients (33.3 % vs 23.3 %) 
3. Higher incidence of low HDL among male patients (80 % vs 55.6 %) 
4. Higher incidence of prediabetes among both sexes, 48.3 % and 55.6 % in males, 
females respectively. 
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5. Incidence of smoking among males was 60 % whereas none of the female patients 
were smoking 
6. Male patients underwent primary PCI more frequently than female patients(27.9 % vs 
14.3 %) 
7. Vasculitis was presents in 22.2 % of females and none of the males. 
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DISCUSSION 
 
There are many studies of premature CAD conducted in different countries which 
looked into different aspects of the disease like genetic factors, etiological factors, 
angiographic findings and outcomes. The most consistent findings in all these studies are the 
predominance of male sex, higher incidence of smoking and dyslipidemia.   
In our study, patients up to 40 years of age were selected, according to the criterion in 
the literature, which considers a patient with acute myocardial infarction young if he or she is 
40 or 45 years old1-5.  The similarity of age between females and males allowed an adequate 
comparison between the sexes. 
Sex seems to influence the clinical presentation of acute myocardial infarction. 
Females with acute myocardial infarction are 10 years older than males.  In our study, males 
outnumbered females by more than six times (60 vs 9). Male predominance has been noted in 
all similar studies in literature.  
In a study conducted in Brazil147, which specifically compared premature CAD in 
male, female patients, no significant difference was observed between the sexes in risk 
factors, pattern of coronary artery obstruction and left ventricular function. Female sex and 
diabetes were independent factors related to the occurrence of reinfarction and death.. 
When individual risk factors were compared among male and female patients of our 
study, male patients had a higher prevalence of hypertension (23.3 % versus 11.1 %) whereas 
female patients had higher prevalence of diabetes (33.3 % versus 23.3 %). Prediabetes 
prevalence was high in both groups (48.3 % & 56.6 %). Prevalence of high LDL (78.3 % & 
77.8 %) and hypertriglyceridemia (51.7 % & 44.4 %) are comparable between sexes but 
prevalence of low HDL is significantly high among males (80 % & 55.6 %). Similar result 
for low HDL has been observed in the Brazilian study147. 
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Among our patients, only male patients had history of smoking (60 %) and alcoholism 
(35 %). Hyperhomocysteinemia was present only among male patients, the incidence of 
which was 21.75 % in our study.  
Vasculitis was present only among female patients, the incidence of which is 22.2 %. 
Vasculitis is an important cause of MI in patients with normal coronaries which needs to be 
looked for148. 
Haemoglobin level of more than 17 grams % was noted only among male patients 
(8.3 %) which can be explained by the high incidence (60 %) of smoking only among males 
in our study. Age and sex related increases in iron stores have been linked to the pathogenesis 
of several common diseases, including atherosclerosis. Interest in this hypothesis is 
stimulated by its capacity to explain the sex difference in atherosclerotic diseases and the 
option of preventive lowering of iron stores by repeated phlebotomy. Iron catalyzes the 
formation of reactive oxygen species through the Fenton and Haber–Weiss reactions. Free 
radicals cause lipid peroxidation, leading to the modification of LDL at the molecular level, 
facilitating its deposition and leading to the formation of atherosclerotic plaque.149 
Divergent information is available on the relationship between body iron stores and 
CAD. It has been shown that the concentrations of body iron stores are a strong predictor of 
CAD in eastern Finnish men.150 Routine voluntary blood donation is associated, 
epidemiologically, with reduced coronary risk.151-2 Furthermore, Kiechl et  al153 found a 
highly significant correlation between serum ferritin concentration and pathologic carotid 
artery wall thickening in a longitudinal cohort study. However, several epidemiologic studies 
investigating the association between high body iron stores and risk of cardiovascular disease 
in humans have not provided positive results.154-5 The association between ferritin and CAD 
was more pronounced in male patients <50 years. Ferritin was significantly higher in diabetic 
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male patients in comparison with nondiabetic male patients. No association was observed 
between ferritin and CAD among female patients.156 
Mode of presentation was comparable in both males and females. They are more 
likely to present as STEMI (71.7 % & 77.8 %) than as NSTEMI (28.3 % & 22.2 %) 
When treatment was analyzed, male patients underwent primary PCI more frequently 
than female patients (27.9 % versus 14.3 %). In the Brazilian study, the time interval between 
symptom onset and treatment was longer in females, who underwent thrombolysis and 
angioplasty less frequently than males did, but not myocardial revascularisation. 
Previous similar studies in the literature have shown a lower incidence of 
hypertension and diabetes mellitus in young patients presenting with myocardial infarction 
compared with older patients with MI. In our study the prevalence of hypertension was 21.7 
%, whereas the prevalence of diabetes mellitus was 24.6 %.  Hypertension was more 
prevalent among males (23.3 % vs 11.1 %) and diabetes was more prevalent among females 
(33.3 % vs 11.1 %). 
               The incidence of prediabetes was 49.27 % in our study, which is a new and 
alarming finding. Its prevalence is high irrespective of sex, income and urban or rural origin. 
This correlates with the rising incidence of sedentary lifestyle, lack of physical activity and 
unhealthy food habits among Indians.  The higher prevalence of prediabetes among patients 
with MI at young age indicates that endothelial dysfunction is more likely to occur in the 
early stages of diabetes or prediabetes which predispose to myocardial infarction. Hence, it 
becomes necessary to identify and target these patients with primary prevention. 
In the Chennai based CUPS STUDY, The overall prevalence rate of CAD is 11.0%. 
The prevalence rates of CAD were 9.1%, 14.9% and 21.4% in those with normal glucose 
tolerance (NGT), impaired glucose tolerance (IGT) and diabetes, respectively. 
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             In a meta analysis of studies of prediabetes133, 18 publications were analysed. 
Impaired fasting glucose and IGT are associated with modest increases in the risk for 
cardiovascular disease.157 Diabetes and CAD occur together more commonly than usually 
recognized, with the negative impact of dysglycemia apparent before diabetes. In the 
Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe (DECODE), 
a group of studies of 25,000 individuals were analyzed together. It showed that 2 hr glucose 
levels increased with age, with less evidence for such an increase in fasting glucose and  2 hr 
glucose predicted all-cause mortality and CVD risk better than fasting glucose134. There was 
a continuous increase in CVD risk with increasing 2 hr glucose, a phenomenon not clearly 
found for fasting glucose. Adjusting for fasting glucose, 2 hr glucose continued to 
significantly predict increased CVD, coronary heart disease (CHD), and total mortality. 
Furthermore, although the absolute risk was greater for diabetic individuals, in DECODE 
there were more excess deaths related to hyperglycemia among men with IGT than among 
those with diabetes because of the greater prevalence of the former group, implying that this 
group could benefit from treatment.  Diabetes Epidemiology: Collaborative analysis Of 
Diagnostic criteria in Asia (DECODA), a similar study, showed similar data, with  the effect 
of fasting glucose on risk eliminated by adjusting for 2 hr glucose, whereas adjustment for 
fasting glucose failed to eliminate the association of 2 hr glucose with CVD, CHD, stroke, 
and total mortality158    
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European Society of Cardiology recommendation on Prediabetes and CAD 
Recommendation 
 
Class   Level of 
evidence 
Relationship between hyperglycaemia and CVD is a continuum. For 
each 1% increase of HbA1c there is a defined increased risk for CVD 
I A A 
Risk of CVD for people with overt diabetes is increased by 2-3 times for 
men and 3-5 times for women when compared with people without diabetes                
I A 
 
A 
Post-prandial glucose predicts future risk for CVD better than fasting 
glucose, and elevated post-prandial glucose also predicts increased CV risk 
in subjects with normal fasting glucose levels   
I A A 
Improved control of post-prandial glycaemia may lower CV risk and 
mortality       
 
IIb C C 
Glucometabolic perturbations carry a particularly high risk for CV 
morbidity and mortality in women, who in 
this respect need special attention 
IIa B B 
People with diabetes and IGT have an increased risk for stroke                                I A 
 
A 
In stroke patients, unrecognized hyperglycaemia is mostly high post-load 
glucose seen in  the OGTT, whereas the measurement of fasting glucose  
is insensitive in detecting   unrecognized hyperglycemia                                                                  
   
I B 
 
B 
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The prevalence of abnormal lipid profile is very high among the patients in our study which 
was the finding in similar studies in literature. Our patients had higher prevalence of high 
LDL (78.26 %) and low HDL(76.82 %) compared to high triglyceride levels (50.72 %). 
Incidence of low HDL was higher among males than females (80 % vs 55.6 %) 
                 In the CUPS (Chennai Urban Population Study)159, Prevalence of CAD increased 
with an increase in total cholesterol, LDL cholesterol, triglycerides and total cholesterol/high-
density lipoprotein  ratio. Multiple logistic regression analysis identified age and LDL 
cholesterol as the risk factors for CAD. It has been reported in the literature that the isolated 
value of LDL-cholesterol plays a less significant role as a cardiovascular risk factor in 
females as compared with that in males160-62. On the other hand, a low HDL-cholesterol level 
has been considered an important predictor of mortality among females. A meta-analysis 
carried out at the National Heart, Lung, and Blood Institute has shown that total 
Hypercholesterolemia and high LDL cholesterol levels correlate with a higher cardiovascular 
mortality in females younger than 65 years old, but not in the elderly 40. The role of 
triglycerides as an independent risk factor of coronary artery disease is still controversial. 
Some admit their greater importance in females, especially in the elderly 42-45, mainly due 
to an increase in thrombotic risk.  
                Chen118 (1995) stated that in addition to previously identified risk factors such as 
family history and smoking, high plasma triglyceride and low HDL cholesterol levels are 
associated with premature coronary artery disease. 
                Tewari 119(2005) observed significant differences in the clinical, biochemical and 
angiographic profile of young patients with coronary artery disease as compared to elderly 
patients in north India. Young patients had more atherogenic lipid profile, higher prevalence 
of smoking and more frequent single vessel disease. He stated that total cholesterol/ high 
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density lipoprotein cholesterol ratio was a better predictor of coronary artery disease as 
compared to individual lipid levels.        
Hyperhomocysteinemia ( >15 mcmol %)was present in 13 patients(18.8 %), only 
among male patients, the significance of which is difficult to assess, given the small number 
of patients studied. 
Vasculitis was present in 2 of 9 female patients (22.2 %) and none of the male 
patients. Davies 120(2007) highlights the diagnosis of antiphospholipid syndrome (APS) in 
five young patients presenting with myocardial infarction and normal coronary arteries at 
angiography. He states that the diagnosis of antiphospholipid antibody syndrome makes a 
crucial decision in treatment as they do not require anti atherosclerotic treatment but they do 
well on high dose warfarin. 
Majority of the young MI patients had good left ventricular systolic function with 
ejection fraction more than 50 % (78.25 %).  18. 95 % of patients had mild LV dysfunction 
and 2.9 % of patients had moderate LV dysfunction. None of the patients had cardiogenic 
shock. 
Among the patients presented with STEMI, 70 % of patients underwent 
revascularisation either with thrombolysis (44 %) or primary PCI (26 %). Remaining 30 % 
were managed conservatively. The most common reason for this is late presentation. 
The most common infarct related artery in our study is left anterior descending artery 
(47.8 %) followed by right coronary artery in 8.7 % of patients. Left circumflex artery is least 
commonly involved (5.8 %). Younger patients have a higher incidence of normal coronary 
arteries, mild luminal irregularities, and single vessel coronary artery disease than do older 
patients. 
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                 One of the largest reports of angiographic findings in young patients with CHD 
comes from a sub study of the CASS trial163, which compared the results of coronary 
angiography in 504 young men (≤ 35 years of age) and women (≤ 45 years of age) with a 
history of an MI to those in over 8300 older patients. The following significant differences 
were noted: 
· Normal coronary arteries were more common in the young patients (18 versus 3 
percent). Young women had a higher frequency of angiographically normal coronary 
arteries than young men, despite a 10 year age difference in the definition of "young." 
· Single vessel coronary disease was more common (38 versus 24 percent) and three 
vessel disease was less common (14 versus 39 percent) in the younger patients. 
· Although some series165-6 have shown a predilection for involvement of the left 
anterior descending artery in young patients, this was not found in the CASS sub 
study. 
· In another large series of 823 young patients with CHD169, single vessel disease was 
present in 55 to 60 percent. 
           Spontaneous coronary artery dissection is a rare cause of acute MI that is more 
common in younger patients (under age 50) and in women. In women, the risk of 
spontaneous coronary dissection appears to be increased during the peripartum period.  
           Kawasaki disease is one of the most important cause of coronary vasculitis, leading to 
coronary aneurysm formation in 20 to 25 percent of untreated patients during the acute stage 
of the disease. Nearly half of acute aneurysms regress, but approximately 20 percent lead to 
the development of coronary stenosis in the long term. Patients can present with MI or 
sudden cardiac death (SCD).  
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The prevalence of significant coronary disease is lower in women presenting with 
chest pain than in men 168-9. This was illustrated in a report of 886 patients referred for 
angiographic evaluation of presumed angina, 23 percent of whom were women168. Normal 
coronary arteries were much more common in women (41 versus 8 percent in men). 
Myocardial ischemia is present in a minority of the women with normal coronary arteries (20 
percent in two reports), perhaps due to microvascular disease170-1.  
Pineda121 (2008) conducted a retrospective case control study of premature coronary 
disease with consecutive older patients as controls. It showed that premature CAD is a more 
frequent entity and it affects predominantly the male sex and shows high prevalence of 
cardiovascular risk factors, mainly tobacco, dyslipidemia and family history of ischemic heart 
disease with higher prevalence of single vessel disease and lower initial morbidity.           
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Comparison with other similar studies 
 Our study J.Pineda et 
al 
Lijia chen 
et al 
Ranjith et al Hosseini 
et al 
Fournier 
et al 
Total number 69 200 100 males 245 108 108 
Age <40 yrs < 45 yrs <40 yrs  <35 yrs <40 yrs 
Males  86.95 % 92.5 % 100  92.6 % 94.5 % 
Hypertension  21.7 % 28.5 % 25% 21.63 % 13.9 % 24 % 
Diabetes  24.6 % 11.5 % 5% 19.2 % 10. 3 % 12 % 
Prediabetes  49.27 %      
Smoking  53.6 % 86.1 % 73 % 74.3 % 39.8 % 94.5 % 
Family 
History 
11.6 % 41.5 % 39 %  34.6 %  
Alcohol  30.4 %     22 % 
Obesity  7.2 %     37 % 
LDL > 100 
mg/dl 
78.26 % 73.5 %   47.2 % 48 % 
HDL < 40 
mg/ dl 
76.82 %      
TGL > 150 
mg/dl 
50.72 %      
Hb >17 gm % 7.25 %      
STEMI  72.5 %      
LV EF < 50 
% 
21.75 %     40 % 
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Comparison of Angiographic findings 
 
 Our study Fournier et al Lijia et al Hosseini et al 
Total number 69 87 100 108 
Single vessel 43(62.32 %) 43(49 %) 54 37 (34.3 %) 
Double vessel 7(10.15 %) 18(21 %) 36 38 (35.2 %) 
Triple vessel 7(10.15 %) 7(8 %) 10  
LAD 33(47.8 %) 32(36.8 %) 37 % 60 (55.6 %) 
RCA 6(8.7 %) 40(46 %) 36 % 42 (38.9 %) 
LCX 4(5.8 %) 20(23 %) 27 % 27 (25 %) 
Recanalised 12(17.4 %) 17(20 %)  18.5 % 
Thrombus 26(37.68 %)    
   
   
Limitations of the study 
· This is single centre study. 
· Number of patients studied is small. 
· Duration of study is short; hence follow up of patients was not included in the study. 
· Large prospective studies with longer follow up are required for better understanding 
and management of premature CAD. 
 
  
  
 
 
CONCLUSION 
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CONCLUSION 
 
                 Although myocardial infarction, fortunately, is an uncommon entity in young adults 
aged less than 40 years, it constitutes an important problem for both the patient and the 
treating physician. They also have a different risk factor profile, clinical presentation, and 
prognosis in comparison with older patients, which has to be taken into consideration when 
treating them. The increasing prevalence of risk factors for CAD among young individuals 
may set up an alarming trend.  
In our study, male sex, dyslipidemia and smoking are the most important risk factors 
for premature CAD which correlates with the results of previous similar studies. Next to 
them, prediabetes is alarmingly high in our study patients with a prevalence of 49.27 %.  Its 
prevalence is high irrespective of sex, income and rural or urban origin. This is a new 
observation and indicates the growing trend of unhealthy lifestyle and food habits among 
young Indian population. Hb A1c needs to be checked in all patients so that early treatment 
could be initiated even before frank diabetes sets in. 
Smoking was more prevalent among rural patients (85.7 %) compared to urban 
patients (39.6 %) in our study. No significant difference in risk factor profile, presentation 
was observed among patients with varying income. 
Acute STEMI is the most common presentation (72.5 %) in our study and Left 
ventricular dysfunction is less common (21.75 %).  Angiographically, single vessel disease is 
the most common presentation (62.32 %) with the most common vessel involved being left 
anterior descending artery (47.8 %).  Male patients, urban residents and high income patients 
are more likely to undergo primary PCI. 
Early stabilisation should be followed by risk stratification, and early 
revascularisation, where appropriate, should be offered as it carries a better clinical outcome. 
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Risk factors modification, regular physical activity and healthy diet should be emphasised 
among young patients for primary prevention of premature CAD.  
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                                                        APPENDIX   I 
                                                    ABBREVIATIONS 
AHA               -           American Heart Association 
AMI     -        Acute myocardial infarction  
CAD     -         Coronary artery disease  
STEMI    -     ST elevation myocardial infarction 
CVD     -        Cardio vascular disease 
MI     -         Myocardial infarction 
NHLBI   -  National Heart, Lung, and Blood Institute  
LVF   -        Left ventricular failure 
GISSI   -         Italian Group for the Study of Streptokinase in Myocardial Infarction 
ISIS    -           Second International Study of Infarct Survival   
SAVE   -        Survival and Ventricular Enlargement 
ACEI    -         Angiotensin converting enzyme inhibitors  
LVAD  -         Left ventricular assist devices  
SERCA  -     Sarcoplasmic reticulum Ca2+ ATPase 
UA     -           Unstable angina 
NSTEMI  -      Non ST segment elevation myocardial infarction 
LMWH    -       Low-molecular-weight heparin  
LDL     -           Low-density lipoprotein     
RNA    -    Ribo nucleic acid  
HMG Co A     -     3-Hydroxy-3-methylglutaryl coenzyme A  
HDL     -        High-density lipoprotein   
CYP      -       Cytochrome P 
WHO     -      World Health Organisation 
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IHD      -     Ischeimic heart disease 
HIV       -    Human immunodeficiency virus 
AIDS        -   Acquired immune deficiency syndrome 
ARB        -     Angiotensin Receptor Blocker 
APO        -    Apolipoprotein 
PROCAM    -   Prospective Cardiovascular Munster Heart Study 
PAR         -    Population attributable risk 
OR        -      Odds ratio 
CHD     -    Coronary heart disease 
ACS       -        Acute coronary syndrome 
WC        -      Waist circumference 
AGE     -      Advanced glycation end products 
 ICAM     -   Intracellular adhesion molecules 
 IL       -     Interleukin 
 MCP    -   Monocyte chemo attractant protein 
 NF      -    Nuclear factor 
 RAGE     -    Receptor for advanced glycation end products 
 VCAM    -    Vascular cell adhesion molecules 
PAI      -     Plasminogen activator inhibitor 
RR       -     Relative risk  
 IGT      -     Impaired glucose tolerance  
ADA      -   American diabetic association 
NCEP   -    National Cholesterol Education Program 
SAM NECP     -   South Asian Modified National Cholesterol Education Program 
BMI     -      Body mass index 
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MS      -   Metabolic syndrome 
UKADS     -     United Kingdom Asian Diabetes Study  
IDF     -        International Diabetic Federation 
LV      -      Left ventricle 
ICU      -  Intensive care unit 
ECG     -     Electrocardiogram 
Hb A1c     -    Hemoglobin A1c 
BP     -       Blood pressure 
2D        -     Two dimentional 
PCI       -      Percutaneous coronary intervention 
NGT      -    Normal glucose tolerance 
DECODE    -    Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria   
     in Europe  
OGTT      -    Oral Glucose Tolerance Test 
CUPS     -      Chennai urban population study 
APS      -       Antiphospholipid syndrome 
CASS     -      Coronary artery surgery study 
KD        -       Kawasaki disease 
SCD     -        Sudden cardiac death 
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APPENDIX II 
PROFORMA 
Name :                                                                   Age :                            
OP No :                                                              DOA :                                               DOD : 
Residence :        Corporation                     Municipality                                           Village     
 Income               < 72,000                    72,000- 2 lakhs                   2-4 lakhs                      > 4 lakhs 
Married                         
Risk Factors  
Hypertension                           Diabetes                         Insulin requiring                          Dyslipidemia                            
Smoking                                   Family h/o CAD             Vasculitis                                       AF                                      
Alcohol                                     BMI                        Hyperhomocysteinemia       
Investigations                   
Hb  A1c          < 5.5                    5.5 - 6.4                     > 6.5 
LDL                < 100                   100-130                    130-160                       > 160            
HDL               <20                      21-39                          40- 49                 50-59                >  60 
TGL              <150                    151-199                      200-249               >250     
Hb              < 10                       10.1- 13                    13.1-15.0                   15.1- 17.0                 > 17 
MCV          Normal                    Low                        High          
Clinical Presentation 
ACS                       STEMI               NSTEMI/USA                 Chronic IHD                    table Angina                       
 Ischemic   HF                 Silent IHD              
Echo                  EF                 >50%                    40-50 %                      30-40%                      <30% 
In hospital complications          
Death                       Recurrent MI                       CVA                             Mechanical                    
MR/VSR 
 Arrhythmias                                Pericardial effusion                                           
Treatment                    Thrombolysis                             Primary PCI                      Conservative 
Angiographic findings 
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SVD                                                  DVD                                  TVD 
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S.No Name Age Gender Residence Income Married
Hyperten
sion
Diabe
tes
Insulin 
requiring
Dyslipide
mia Smoking
Family h/o 
CAD Vasculitis AF Alcohol BMI
1 Senthilkumar                  35 1 1 1 2 2 2 2 1 1 1 2 2 1 2
2 Nizaar Ali                    35 1 2 1 2 2 2 2 2 1 2 2 2 2 2
3 Lakshmi kandan                38 1 1 1 2 1 2 2 2 2 2 2 2 2 2
4 Shakthivel S                  37 1 3 1 2 2 2 2 2 1 1 2 2 2 2
5 Thangaraj                     32 1 2 1 2 2 2 2 1 2 2 2 2 1 2
6 Tajudeen                      38 1 3 1 2 2 2 2 2 1 2 2 2 2 2
7 Angusamy                      36 1 2 4 2 1 1 2 1 1 2 2 2 2 2
8 Sivasudan                     39 1 2 3 2 2 1 2 2 2 2 2 2 2 2
9 Arignar Anna                  37 1 2 4 2 2 2 2 1 1 1 2 2 1 2
10 Chinnasamy                    37 1 3 2 2 1 2 2 1 1 2 2 2 2 2
11 Vijayakumar                   35 1 2 2 2 2 2 2 2 1 2 2 2 1 2
12 Balraj                        40 1 3 1 2 2 2 2 2 1 2 2 2 2 2
13 Prabhu S                      38 1 2 4 2 2 2 2 2 1 2 2 2 1 2
14 Jegadesan                     40 1 3 4 2 2 2 2 1 2 2 2 2 2 2
15 Raja                          34 1 1 1 2 2 2 2 2 1 2 2 2 1 2
16 Unnikrishnan                  28 1 2 2 2 2 2 2 1 1 2 2 2 1 2
17 Selvaraj                      40 1 1 1 2 2 1 2 2 2 2 2 2 2 2
18 Gandhimathi                   38 2 1 1 2 2 1 1 1 2 2 2 2 2 2
19 Ganesan                       34 1 3 2 2 2 1 2 2 2 2 2 2 2 2
20 Nandhini                      38 2 2 1 2 1 1 2 2 2 2 2 2 2 2
21 Karthick                      25 1 3 2 1 2 2 2 2 1 2 2 2 2 2
22 Anandhan                      40 1 3 1 2 2 2 2 1 1 2 2 2 1 2
23 Gunasekar                     35 1 2 3 2 2 1 2 1 1 2 2 2 1 2
24 Nagaraj                       35 1 1 1 2 2 2 2 2 2 1 2 2 2 2
25 Sivakumar P                   39 1 2 1 2 2 1 2 2 1 2 2 2 2 2
26 Rajendranm                    34 1 1 2 2 2 2 2 P 2 1 2 2 1 2
27 Jagadeesh T                   26 1 3 1 2 2 2 2 1 1 1 2 2 2 2
28 Babu C                        37 1 1 2 2 2 2 2 1 2 2 2 2 1 2
29 Venkatachalam                 40 1 2 2 2 1 2 2 2 2 2 2 2 2 2
30 Elumalai                      40 1 2 1 2 2 2 2 2 1 2 2 2 1 2
31 Maheshwaran                   39 1 3 1 2 2 2 2 2 1 1 2 2 1 2
32 Prakash                       29 1 2 2 1 2 2 2 2 2 2 2 2 2 2
33 Kulanthaivel                  40 1 3 2 2 2 2 2 1 1 2 2 2 1 2
34 Vijayakumar                   37 1 1 2 2 1 1 2 2 1 2 2 2 1 2
MASTER CHART
Risk factors
S.No Name Age Gender Residence Income Married
Hyperten
sion
Diabe
tes
Insulin 
requiring
Dyslipide
mia Smoking
Family h/o 
CAD Vasculitis AF Alcohol BMI
35 Chinnasamy                    38 1 3 1 2 1 2 2 2 1 2 2 2 2 2
36 Mahendran                     38 1 3 4 2 1 2 2 2 1 2 2 2 2 2
37 Zaltihar Ahmed Basha          38 1 1 2 2 1 2 2 2 2 2 2 2 2 2
38 Subramaniam                   35 1 3 1 2 2 2 2 2 1 2 2 2 2 2
39 Selvaraj                      35 1 3 2 1 1 1 2 2 1 2 2 2 2 1
40 Anandhan B                    40 1 1 1 2 2 2 2 2 2 2 2 2 2 2
41 Kumarasamy                    32 1 2 1 2 2 1 2 2 2 2 2 2 2 2
42 Manikandan                    40 1 1 1 2 2 1 2 2 2 2 2 2 2 1
43 Geetha                        40 2 1 1 2 2 1 1 2 2 2 2 2 2 2
44 Sarojini                      40 2 1 1 2 2 2 2 2 2 2 2 2 2 2
45 Vimalathithan                 37 1 3 4 2 1 2 2 2 1 2 2 2 2 1
46 Velusamy                      40 1 2 4 2 2 2 2 2 2 2 2 2 2 2
47 Murugesan                     33 1 2 2 2 2 2 2 1 1 2 2 2 2 2
48 Saravannan                    38 1 3 2 2 1 2 2 2 1 2 2 2 2 2
49 Srinivasan V                  36 1 3 1 2 2 2 2 2 2 2 2 2 1 2
50 Hemalatha.S                   22 2 1 3 1 2 2 2 2 2 2 1 2 2 2
51 Robert Kennedy                37 1 1 2 2 2 1 2 1 2 2 2 2 2 2
52 Saradha                       33 1 2 1 2 2 2 2 2 2 2 2 2 2 2
53 Saravanan G                   38 1 2 2 1 1 2 2 2 2 2 2 2 2 2
54 Subramanian                   40 1 3 2 2 2 2 2 2 1 2 2 2 2 2
55 Senthilkumar A                33 1 1 1 2 2 2 2 2 2 2 2 2 2 1
56 Pandiyan                      35 1 1 1 2 2 2 2 1 1 1 2 2 2 2
57 Palanisamy A                  32 1 1 2 2 2 2 2 1 1 2 2 2 1 2
58 Shanmugasundaram              39 1 1 3 2 2 1 2 1 2 2 2 2 1 2
59 Ratna                         40 1 1 1 2 2 2 2 2 2 2 2 2 2 2
60 George Saman                  30 1 1 1 2 2 2 2 2 1 2 2 2 2 2
61 Mohanasundaram                35 1 1 2 2 2 1 2 2 2 2 2 2 2 1
62 Mohan C                       38 1 3 2 2 2 1 2 1 1 2 2 2 1 2
63 Marimuthu                     37 1 2 2 1 2 2 2 2 1 2 2 2 2 2
64 Gurusamy                      32 1 1 1 2 1 2 2 2 2 2 2 2 1 2
65 Marimuthu                     37 1 2 2 2 2 2 2 2 2 2 2 2 2 2
66 Saira Moosa                   36 2 1 3 2 2 2 2 2 2 2 1 2 2 2
67 Ragupathy                     37 1 1 1 2 2 2 2 1 1 2 2 2 1 2
68 Palanisamy                    40 1 1 3 2 1 2 2 2 1 2 2 2 2 2
69 Rejendran K                   40 1 3 1 2 2 2 2 2 1 2 2 2 2 2
S.No Name
Hyperhomo
cystenemia HbA1c LDL HDL TGL Hb MCV ACS STEMI NSTEMI
Chronic 
IHD
Stable 
Angina
Ischemic 
HF
Silent 
IHD
Echo 
EF Death
Recurrent
 MI CVA Mechanical
1 Senthilkumar                  1 2 2 2 3 5 3 2 1 2 2 2 2 2 1 2 2 2 2
2 Nizaar Ali                    2 2 1 2 1 3 1 2 1 1 2 2 2 2 1 2 2 2 2
3 Lakshmi kandan                2 1 2 1 1 4 1 2 1 2 2 2 2 2 1 2 2 2 2
4 Shakthivel S                  2 1 2 2 3 3 1 2 1 2 2 2 2 2 1 2 2 2 2
5 Thangaraj                     1 1 1 2 1 2 2 2 1 2 2 2 2 2 1 2 2 2 2
6 Tajudeen                      2 2 3 3 1 3 1 2 1 2 2 2 2 2 1 2 2 2 2
7 Angusamy                      2 3 4 2 1 3 1 2 1 2 2 2 2 2 1 2 2 2 2
8 Sivasudan                     2 1 4 3 4 3 1 2 2 2 2 2 2 2 1 2 2 2 2
9 Arignar Anna                  2 3 3 2 4 4 1 2 1 2 2 2 2 2 1 2 2 2 2
10 Chinnasamy                    2 1 2 2 2 4 1 2 2 1 2 2 2 2 1 2 2 2 2
11 Vijayakumar                   2 1 4 2 4 4 1 2 1 2 2 2 2 2 2 2 2 2 2
12 Balraj                        2 2 2 2 1 3 1 2 2 1 2 2 2 2 1 2 2 2 2
13 Prabhu S                      2 2 3 2 3 3 1 2 1 2 2 2 2 2 1 2 2 2 2
14 Jegadesan                     2 3 4 2 2 3 1 2 1 2 2 2 2 2 3 2 2 2 2
15 Raja                          2 1 4 4 1 3 3 2 1 2 2 2 2 2 2 2 2 2 2
16 Unnikrishnan                  2 2 3 2 3 2 2 1 2 2 2 2 2 1 2 2 2 2
17 Selvaraj                      2 1 4 2 2 4 1 2 2 2 2 1 2 2 1 2 2 2 2
18 Gandhimathi                   2 3 4 3 2 3 1 2 1 2 2 2 2 2 1 2 2 2 2
19 Ganesan                       2 1 2 4 1 3 1 2 1 2 2 2 2 2 1 2 2 2 2
20 Nandhini                      2 3 3 2 2 3 1 1 2 2 2 2 1 2 1 2 2 2 2
21 Karthick                      2 1 3 3 1 4 1 2 1 2 2 2 2 2 1 2 2 2 2
22 Anandhan                      1 2 2 4 1 3 1 2 1 2 2 2 2 2 2 2 2 2 2
23 Gunasekar                     2 3 4 2 4 4 3 2 1 2 2 2 2 2 1 2 2 2 2
24 Nagaraj                       1 1 3 2 1 3 3 2 1 2 2 2 2 2 1 2 2 2 2
25 Sivakumar P                   2 3 3 2 4 4 3 2 2 1 2 2 2 2 1 2 2 2 2
26 Rajendranm                    1 3 1 2 1 3 1 2 1 2 2 2 2 2 1 2 2 2 2
27 Jagadeesh T                   2 2 1 2 1 3 1 2 1 2 2 2 2 2 1 2 2 2 2
28 Babu C                        2 2 4 2 2 1 2 2 1 2 2 2 2 2 2 2 2 2 2
29 Venkatachalam                 2 2 2 2 1 4 1 2 1 2 2 2 2 2 1 2 1 2 2
30 Elumalai                      1 1 2 2 1 5 3 2 1 2 2 2 2 2 1 2 2 2 2
31 Maheshwaran                   1 2 2 3 4 4 1 2 2 2 2 2 2 2 1 2 2 2 2
32 Prakash                       2 2 2 2 1 2 1 2 1 2 2 2 2 2 1 2 2 2 2
33 Kulanthaivel                  2 3 4 2 2 4 3 2 2 1 2 2 2 2 1 2 2 2 2
34 Vijayakumar                   2 2 4 4 4 4 3 2 1 2 2 2 2 2 2 2 1 2 2
Investigations Clinical Presentation In Hospital Complications                                        In Hospital Complications
S.No Name
Hyperhomo
cystenemia HbA1c LDL HDL TGL Hb MCV ACS STEMI NSTEMI
Chronic 
IHD
Stable 
Angina
Ischemic 
HF
Silent 
IHD
Echo 
EF Death
Recurrent
 MI CVA Mechanical
35 Chinnasamy                    2 2 2 2 1 4 1 2 1 2 2 2 2 2 1 2 2 2 2
36 Mahendran                     2 2 1 2 1 5 1 1 2 2 2 2 2 2 1 2 2 2 2
37 Zaltihar Ahmed Basha          2 2 2 2 1 3 1 2 1 2 2 2 2 2 1 2 2 2 2
38 Subramaniam                   2 2 2 2 3 4 1 2 1 2 2 2 2 2 1 2 2 2 2
39 Selvaraj                      2 2 3 2 2 2 1 2 2 2 2 2 2 2 1 2 2 2 2
40 Anandhan B                    1 2 3 3 2 4 1 2 1 2 2 2 2 2 2 2 2 2 2
41 Kumarasamy                    2 2 1 2 1 3 1 2 1 2 2 2 2 2 1 2 2 2 2
42 Manikandan                    2 1 3 1 2 2 1 2 2 2 2 2 2 2 1 2 2 2 2
43 Geetha                        2 3 4 2 2 3 1 2 1 2 2 2 2 2 1 2 1 2 2
44 Sarojini                      2 2 2 2 1 2 1 2 1 2 2 2 2 2 2 2 2 2 2
45 Vimalathithan                 2 2 2 2 1 2 1 2 1 2 2 2 2 2 1 2 2 2 2
46 Velusamy                      1 1 4 3 1 4 1 2 1 2 2 2 2 2 1 2 2 2 2
47 Murugesan                     2 2 4 2 3 3 2 2 1 2 2 2 2 1 2 2 2 2
48 Saravannan                    1 2 3 2 2 4 1 2 2 2 2 2 2 2 1 2 2 2 2
49 Srinivasan V                  1 2 1 2 1 3 1 2 1 2 2 2 2 2 2 2 2 2 2
50 Hemalatha.S                   2 2 1 3 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2
51 Robert Kennedy                2 2 4 3 1 2 1 2 1 2 2 2 2 2 1 2 2 2 2
52 Saradha                       2 2 3 2 1 2 2 2 2 1 2 2 2 2 1 2 2 2 2
53 Saravanan G                   2 2 2 2 1 5 1 2 1 2 2 2 2 2 2 2 2 2 2
54 Subramanian                   2 1 1 2 1 4 1 2 1 2 2 2 2 2 1 2 2 2 2
55 Senthilkumar A                2 1 3 3 4 3 3 2 1 2 2 2 2 2 1 2 2 2 2
56 Pandiyan                      2 1 2 2 4 4 2 2 1 2 2 2 2 3 2 2 2 2
57 Palanisamy A                  1 2 2 2 2 3 1 2 1 2 2 2 2 2 1 2 2 2 2
58 Shanmugasundaram              2 3 2 3 1 4 1 2 2 1 2 2 2 2 1 2 2 2 2
59 Ratna                         2 2 2 3 1 2 2 2 1 2 2 2 2 2 1 2 2 2 2
60 George Saman                  2 1 1 2 1 5 1 2 1 2 2 2 2 2 1 2 2 2 2
61 Mohanasundaram                2 3 1 2 1 3 1 2 2 1 2 2 2 2 1 2 2 2 2
62 Mohan C                       2 3 2 2 2 4 3 2 1 2 2 2 2 2 1 2 2 2 2
63 Marimuthu                     2 3 4 2 2 3 2 2 1 2 2 2 2 2 2 2 2 2 2
64 Gurusamy                      2 2 1 1 4 3 1 2 2 2 2 2 2 2 1 2 2 2 2
65 Marimuthu                     2 2 4 2 2 3 1 2 1 2 2 2 2 1 2 2 2 2 2
66 Saira Moosa                   2 1 1 2 1 1 1 2 1 2 2 2 2 2 1 2 2 2 2
67 Ragupathy                     1 3 2 2 4 4 1 1 2 2 2 2 2 2 1 2 2 2 2
68 Palanisamy                    2 2 1 2 2 4 1 2 1 2 2 2 2 2 1 2 2 2 2
69 Rejendran K                   2 1 1 2 1 3 3 2 1 2 2 2 2 2 2 2 2 2 2
S.No Name MR/VSR Arrhythmias
Pericardial 
Effusion Treatment
LAD+
Diagonal LtCx RCA
Recana
lised Type A Type B1 Type B2 Type C Thrombus
1 Senthilkumar                  2 2 2 2 1 2 2 2 2 2 2 2 1
2 Nizaar Ali                    2 2 2 1 1 2 2 2 2 2 2 2 2
3 Lakshmi kandan                2 2 2 1 1 1 2 2 2 2 2 2 2
4 Shakthivel S                  2 2 2 1 1 2 2 2 2 2 2 2 2
5 Thangaraj                     2 1 2 1 2 2 2 1 2 2 2 2 2
6 Tajudeen                      2 2 2 1 1 2 2 2 2 2 2 2 2
7 Angusamy                      2 2 2 3 1 1 1 2 2 2 2 2 2
8 Sivasudan                     2 2 2 3 1 1 1 2 2 2 2 2 2
9 Arignar Anna                  2 2 2 2 2 1 1 2 2 2 2 2 2
10 Chinnasamy                    2 2 2 3 2 1 2 2 2 2 2 2 2
11 Vijayakumar                   2 2 2 3 1 2 2 2 2 2 2 2 2
12 Balraj                        2 2 2 3 1 2 2 2 2 2 2 2 2
13 Prabhu S                      2 2 2 2 1 2 1 2 2 2 2 2 2
14 Jegadesan                     2 2 2 3 1 1 1 2 2 2 2 2 2
15 Raja                          2 2 2 3 1 2 2 2 2 2 2 2 2
16 Unnikrishnan                  2 2 2 1 2 2 1 2 2 2 2 2 1
17 Selvaraj                      2 2 2 3 2 1 1 2 2 2 2 2 2
18 Gandhimathi                   2 2 2 1 1 2 2 2 2 2 2 2 2
19 Ganesan                       2 2 2 1 1 1 2 2 2 2 2 2 2
20 Nandhini                      2 2 2 3 2 2 2 2 2 2 2 2 2
21 Karthick                      2 2 2 3 1 2 2 2 2 2 2 2 2
22 Anandhan                      2 2 2 1 1 2 2 2 2 2 2 2 2
23 Gunasekar                     2 2 2 2 1 2 2 2 2 2 2 2 2
24 Nagaraj                       2 2 2 2 1 2 2 2 2 2 2 2 2
25 Sivakumar P                   2 2 2 2 2 1 2 2 2 2 2 2 2
26 Rajendranm                    2 2 2 2 1 2 2 2 2 2 2 2 1
27 Jagadeesh T                   2 2 2 1 2 2 2 1 2 2 2 2 2
28 Babu C                        2 2 2 1 1 2 2 1 2 2 2 2 2
29 Venkatachalam                 2 2 2 1 1 2 2 2 2 2 2 2 2
30 Elumalai                      2 1 2 1 1 2 2 2 2 2 2 2 2
31 Maheshwaran                   2 2 2 3 2 2 2 2 2 2 2 2 2
32 Prakash                       2 2 2 3 1 2 2 2 2 2 2 2 2
33 Kulanthaivel                  2 2 2 3 2 1 2 2 2 2 2 2 2
34 Vijayakumar                   2 2 2 1 1 2 2 1 2 2 2 2 1
Angiographic FindingsIn Hospital Complications                                        In Hospital Complications
S.No Name MR/VSR Arrhythmias
Pericardial 
Effusion Treatment
LAD+
Diagonal LtCx RCA
Recana
lised Type A Type B1 Type B2 Type C Thrombus
35 Chinnasamy                    2 2 2 3 1 1 2 2 2 2 2 2 2
36 Mahendran                     2 2 2 3 1 2 2 2 2 2 2 2 2
37 Zaltihar Ahmed Basha          2 2 2 3 1 2 2 2 2 2 2 2 2
38 Subramaniam                   2 2 2 3 1 2 2 2 2 2 2 2 2
39 Selvaraj                      2 2 2 2 1 2 2 2 2 2 2 2 2
40 Anandhan B                    2 2 2 2 1 2 2 2 2 2 2 2 2
41 Kumarasamy                    2 2 2 3 1 2 2 2 2 2 2 2 2
42 Manikandan                    2 2 2 1 2 2 2 2 2 2 2 2 2
43 Geetha                        2 2 2 3 1 2 2 2 2 2 2 2 2
44 Sarojini                      2 2 2 3 2 2 1 2 2 2 2 2 2
45 Vimalathithan                 2 2 2 1 2 2 2 2 2 2 2 1 2
46 Velusamy                      2 2 2 2 1 2 2 2 2 2 2 2 2
47 Murugesan                     2 2 2 3 2 2 1 2 2 2 2 2 2
48 Saravannan                    2 2 2 3 1 2 2 2 2 2 2 2 2
49 Srinivasan V                  2 2 2 3 1 2 2 2 2 2 2 2 2
50 Hemalatha.S                   2 2 2 1 2 2 2 2 2 2 2 2 2
51 Robert Kennedy                2 2 2 2 2 2 1 2 2 2 2 2 2
52 Saradha                       2 2 2 2 1 2 2 2 2 2 2 2 2
53 Saravanan G                   2 2 2 1 1 2 2 2 2 2 2 2 2
54 Subramanian                   2 2 2 1 1 2 2 2 2 2 2 2 2
55 Senthilkumar A                2 2 2 1 1 2 2 2 2 2 2 2 2
56 Pandiyan                      2 2 2 1 2 2 2 2 2 2 2 2 2
57 Palanisamy A                  2 2 2 2 1 2 2 2 2 2 2 2 2
58 Shanmugasundaram              2 2 2 3 1 2 1 2 2 2 2 2 2
59 Ratna                         2 2 2 3 2 2 2 2 2 2 2 2 2
60 George Saman                  2 2 2 3 2 2 2 2 2 2 2 2 2
61 Mohanasundaram                2 2 2 3 1 2 2 2 2 2 2 2 2
62 Mohan C                       2 2 2 3 1 2 2 2 2 2 2 2 2
63 Marimuthu                     2 2 2 1 1 2 2 2 2 2 2 2 2
64 Gurusamy                      2 2 2 3 2 2 2 2 2 2 2 2 2
65 Marimuthu                     2 2 2 3 1 2 2 2 2 2 2 2 2
66 Saira Moosa                   2 2 2 3 2 2 2 1 2 2 2 2 2
67 Ragupathy                     2 2 2 3 1 2 2 2 2 2 2 2 2
68 Palanisamy                    2 2 2 3 2 2 1 2 2 2 2 2 2
69 Rejendran K                   2 2 2 3 1 2 2 2 2 2 2 2 2
    ABSTRACT 
INTRODUCTION:  
Although coronary artery disease (CAD) primarily occurs in patients over the age of 
40, younger patients can still be affected. CAD occurs in Asian Indians 5–10 years earlier 
than in other populations around the world. Traditional risk factors of CAD are prevalent in 
young patients with acute STEMI but with a different pattern compared to their older 
counterparts.  While the literature from developed countries is abundant in data highlighting 
various aspects of myocardial infarction in young patients, only a few studies have been 
published in India.  
MATERIALS AND METHODS 
We conducted a prospective observational study of young patients (age < 40 yr, both 
male and female) admitted with acute coronary syndrome (STEMI and NSTEMI) for a period 
of one year at P S G Hospital. Detailed history of risk factors and demographic profile were 
recorded. Complete blood count, fasting lipid profile, Hb A1c, Echocardiogram were done. 
Treatment modality was noted. Coronary angiogram was done and lesions were analyzed.  
RESULTS:        
 A total of 69 patients were studied. 60 Patient were males (86.95 %), 9 patients were 
females (13.05 %). 26 patients (37.7%) came from corporation, 22 patients (31.9%) came 
from municipalities and 21 patients (30.4%) came from villages. 32(46.42%), 24(34.8 %), 
7(10.1%) patients had low, medium, high income respectively. 17(24.6%) were diabetics, 37 
(53.6%) were smokers, 8 (11.6%) had family H/o CAD, 21(30.4%) were consuming alcohol. 
34(49.27%) had prediabetes, 54(78.26%) had LDL cholesterol > 100mg%, 53(76.82 %) had 
HDL< 40mg %, 35 (50.72%) had TGL level > 150%.  5(7.25%) had Hb >17gm%. 13(18.8%) 
had hyperhomocysteinemia. 50(72.5%) had STEMI, 19(27.5%) had NSTEMI. 54(78.25%) 
had normal LV function. Among the 50 patients who had STEMI, 22 underwent 
thrombolysis (44 %) and 13(26 %) underwent primary PCI. CAG showed single vessel 
disease in 43(62.32 %), double vessel disease in 7(10.15 %), triple vessel disease in 7(10.15 
%), recanalised vessels in 12(17.4 %), thrombus in 26(37.68%). LAD artery is involved most 
commonly in 33(47.8 %) followed by RCA in 6 (8.7 %), LCX in 4(5.8 %). Urban patients 
underwent primary PCI more frequently than rural patients (33.3 % vs 7.14 %). Gender based 
analysis showed higher incidence of hypertension, low HDL among male patients, higher 
incidence of diabetes among female patients, higher incidence of prediabetes among both 
sexes. Incidence of smoking among males was 60 % whereas none of the female patients 
were smoking. Male patients underwent primary PCI more frequently than female patients 
(27.9 % vs 14.3 %) 
CONCLUSION:  
Male sex, dyslipidemia and smoking are the most important risk factors for premature 
CAD. Prediabetes is alarmingly high in our study with a prevalence of 49.27 %.  Its 
prevalence is high irrespective of sex, income and rural or urban origin. Acute STEMI is the 
most common presentation (72.5 %) and LV dysfunction is less common (21.75 %).  
Angiographically, single vessel disease is most common (62.32 %) with the most common 
vessel involved being left anterior descending artery (47.8 %).  Male patients, urban residents 
and high income patients are more likely to undergo primary PCI. 
 
KEY WORDS:   
Premature CAD, young MI, Prediabetes and CAD, Dyslipidenia and CAD, 
Angiographic profile of premature CAD, clinical profile of premature CAD. 
